RayKnowChina Research Map
Shortlist

BeijingPeking Union Medical College / Chinese Academy of Medical Sciences

National Cancer Center / Cancer Hospital, CAMS

中国医学科学院肿瘤医院

Listed for 12 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

Official links opened and checked on 2026-11-08.

Getting in touch

Research at National Cancer Center / Cancer Hospital, CAMS

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌33 papers led1 open trial led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌184 papers led10 open trials led
  3. Hepatocellular carcinoma肝细胞癌103 papers led3 open trials led
  4. Stomach cancer胃癌131 papers led2 open trials led
  5. Osteosarcoma骨肉瘤8 papers led
  6. Gastrointestinal stromal tumour胃肠道间质瘤1 paper led
  7. Neuroblastoma神经母细胞瘤2 papers led
  8. Ewing sarcoma尤文肉瘤1 paper led
  9. Aplastic anaemia再生障碍性贫血3 papers led
  10. Beta thalassaemiaβ 地中海贫血1 paper led
  11. Fanconi anaemia范可尼贫血1 paper led
  12. Idiopathic pulmonary fibrosis特发性肺纤维化1 paper led

Not listed for: Hepatoblastoma, Retinoblastoma, Chordoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Haemophagocytic lymphohistiocytosis, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 33 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 1.4%.

Papers led
33
2021–2025
Trials led
6
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 3320212022: 9920222023: 6620232024: 6620242025: 882025

6 hospitals in Beijing for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2024-08
    Registry
    NCT06509009

    Age 18 years to 75 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  2. Recruiting
    Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07311772

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Hangzhou, Kunming, Nanning, Shanghai, Shantou, Wuzhou, Zhuhai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImaging & AIRadiotherapy techniqueSide effects & quality of life
Departments in papersRadiation oncologyRadiology / nuclear medicinePathology / laboratory medicineENT / head & neck surgery
Papers it led33
  1. The prognostic value of intra- and peritumoral habitat analysis in nasopharyngeal carcinoma: combining IVIM and ASL.2026European radiology
  2. A subregional prediction model for radiation-induced hypothyroidism.2025BMC medical imagingFree full text
  3. The Potential of Model-Free Parameters Derived From IVIM in Evaluating Pathological Indicators and Long-Term Survival in NPC.2025Journal of magnetic resonance imaging : JMRI
  4. A multi-source feature-driven deep learning method to generate linear energy transfer distribution for proton therapy.2025Medical physics
  5. Cavernous sinus syndrome in a patient with occult nasopharyngeal carcinoma: A diagnostic challenge.2025Oral oncology
  6. Model-free parameters derived from intravoxel inherent motion combined with tumor aggressiveness indicators in predicting 5-year treatment outcome in NPC.2025Oral oncology
  7. Development and validation of Prediction models for radiation-induced hypoglossal neuropathy in patients with nasopharyngeal carcinoma.2025Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  8. Pretreatment arterial spin labeling combined with radiological depth of invasion predicts treatment outcome in nonmetastatic NPC.2025Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  9. A feasibility study of dose-band prediction in radiation therapy: Predicting a spectrum of plan dose.2025Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  10. The serological diagnostic value of EBV-related IgA antibody panels for nasopharyngeal carcinoma: a diagnostic test accuracy meta-analysis.2024BMC cancerFree full text
  11. Significance of longitudinal Epstein-Barr virus DNA combined with multipoint tumor response for dynamic risk stratification and treatment adaptation in nasopharyngeal carcinoma.2024Cancer letters
  12. Optimizing Cervical Target Volume in Patients with Nasopharyngeal Cancer Based On Nodal Drainage Distance.2024Clinical cancer research : an official journal of the American Association for Cancer ResearchFree full text
  13. Deep learning method for predicting weekly anatomical changes in patients with nasopharyngeal carcinoma during radiotherapy.2024Medical physics
  14. A deep learning-based method for the prediction of temporal lobe injury in patients with nasopharyngeal carcinoma.2024Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)
  15. The Detection of Nasopharyngeal Carcinomas Using a Neural Network Based on Nasopharyngoscopic Images.2024The Laryngoscope
  16. The utility of texture analysis based on quantitative synthetic magnetic resonance imaging in nasopharyngeal carcinoma: a preliminary study.2023BMC medical imagingFree full text
  17. Histogram analysis of quantitative parameters from synthetic MRI: correlations with prognostic factors in nasopharyngeal carcinoma.2023European radiology
  18. High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal canrcinoma after radiotherapy.2023Journal of translational medicineFree full text
  19. Comprehensive evaluation of similarity between synthetic and real CT images for nasopharyngeal carcinoma.2023Radiation oncology (London, England)Free full text
  20. Efficient segmentation using domain adaptation for MRI-guided and CBCT-guided online adaptive radiotherapy.2023Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  21. Caudal distribution pattern of metastatic neck lymph nodes in nasopharyngeal carcinoma and prognostic significance of nodal spread distances.2023Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  22. Arterial spin labeling and diffusion-weighted imaging for identification of retropharyngeal lymph nodes in patients with nasopharyngeal carcinoma.2022Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  23. Baseline MRI-based radiomics model assisted predicting disease progression in nasopharyngeal carcinoma patients with complete response after treatment.2022Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  24. A comprehensive model based on temporal dynamics of peripheral T cell repertoire for predicting post-treatment distant metastasis of nasopharyngeal carcinoma.2022Cancer immunology, immunotherapy : CIIFree full text
  25. A MRI-based radiomics model predicting radiation-induced temporal lobe injury in nasopharyngeal carcinoma.2022European radiologyRCT
  26. Spatial architecture of regulatory T-cells correlates with disease progression in patients with nasopharyngeal cancer.2022Frontiers in immunologyFree full text
  27. Magnetic resonance imaging-based radiomics model for predicting radiation-induced temporal lobe injury in nasopharyngeal carcinoma after intensity-modulated radiotherapy.2022Head & neck
  28. Irradiation-induced nasopharyngeal necrosis (INN) in newly diagnosed nasopharyngeal carcinoma treated by intensity-modulated radiation therapy: clinical characteristics and the influence of treatment strategies.2022Radiation oncology (London, England)Free full text
  29. MRI-identified multidimensional nodal features predict survival and concurrent chemotherapy benefit for stage II nasopharyngeal carcinoma.2022Radiology and oncologyFree full text
  30. Butein promotes ubiquitination-mediated survivin degradation inhibits tumor growth and overcomes chemoresistance.2022Scientific reportsFree full text
  31. Stage-dependent conditional survival and failure hazard of non-metastatic nasopharyngeal carcinoma after intensity-modulated radiation therapy: Clinical implications for treatment strategies and surveillance.2021Cancer medicineFree full text
  32. Dosiomics-based prediction of radiation-induced hypothyroidism in nasopharyngeal carcinoma patients.2021Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)
  33. A deep-learning method for generating synthetic kV-CT and improving tumor segmentation for helical tomotherapy of nasopharyngeal carcinoma.2021Physics in medicine and biology
Chinese-language papers (not in the count)1
  1. [Analysis of cases of cervical cystic lymph node metastasis with an unknown primary misdiagnosed as branchial cleft carcinoma].2024Zhonghua zhong liu za zhi [Chinese journal of oncology]
All its trials on ClinicalTrials.gov, any status11
  1. Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal CarcinomaRecruitingNCT06509009Lead (inferred)Phase 2Start 2024-08
  2. Optimization of Cervical Nodal CTV for Early and Medium Stage NPCActive, not recruitingNCT05145660Lead (inferred)Phase 3Start 2022-09
  3. Nimotuzumab Combined With VMAT in Elderly Patients With Nasopharyngeal CarcinomaStatus unknownNCT03915132Lead (inferred)Phase 2Start 2019-05
  4. The Role of Induction Chemotherapy for High-risk Locally Advanced Nasopharyngeal Carcinoma in the Era of IMRTCompletedNCT01797900Lead (inferred)Phase 2Start 2013-03
  5. The Role of Concurrent Chemotherapy for Lower Risk Locally Advanced Nasopharyngeal Carcinoma(NPC) in the Era of IMRTStatus unknownNCT01817023Lead (inferred)Phase 3Start 2013-04
  6. The Value of Concurrent Chemoradiotherapy for Stage II Nasopharyngeal CarcinomaCompletedNCT01187238Lead (inferred)Phase 2Start 2010-05
  7. Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral LiquidRecruitingNCT07311772Study sitePhase 3Start 2025-12
  8. Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)Active, not recruitingNCT05587374Study sitePhase 3Start 2023-08
  9. KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT05294172Study sitePhase 3Start 2022-06
  10. KL-A167 Injection in Recurrent or Metastatic Nasopharyngeal CarcinomaCompletedNCT03848286Study sitePhase 2Start 2019-03
  11. The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal CancerCompletedNCT03581786Study sitePhase 3Start 2018-10
More papers found outside PubMed (not counted)24
  1. 710P Mapping the disparity of nasopharyngeal carcinoma burden across 34 provinces in China, 1990-2040, forecasts with scenarios simulation using deep-learning algorithm2025Annals of Oncologyarticle
  2. A randomized, open-label, multicenter, blank-controlled, phase IV clinical trial of Biyan Qingdu Granula in attenuating acute nose and oral damage in patients undergoing radiotherapy for nasopharyngeal carcinoma.2025Journal of Clinical Oncologyconference-abstract
  3. CACA guidelines for holistic integrative management of adolescent and childhood nasopharyngeal carcinoma2025Holistic Integrative Oncologyarticle
  4. Safety and Efficacy of Local Radiotherapy in De Novo Metastatic Nasopharyngeal Carcinoma with Immunochemotherapy: Systematic Review and Meta-Analysis2025International Journal of Radiation Oncology*Biology*Physicsarticle
  5. Tagitanlimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC): Results from a randomized, double-blind, phase 3 study.2025Journal of Clinical Oncologyconference-abstract
  6. A random forest model to predict the efficacy of KL-A167 in previously treated recurrent or metastatic nasopharyngeal carcinoma based on the data from the KL167-II-05-CTP study.2024Journal of Clinical Oncologyconference-abstract
  7. Cross-Technique Transfer Learning to Predict the Dose Distribution for Radiotherapy Planning Based on a Limited Sample Size2024International Journal of Radiation Oncology*Biology*Physicsarticle
  8. Long-Term Treatment Outcomes and Late Toxicity between Childhood and Adult Nasopharyngeal Carcinoma in the Era of IMRT2024International Journal of Radiation Oncology*Biology*Physicsarticle
  9. Neoadjuvant Chemotherapy plus Tislelizumab Followed by Adjuvant Tislelizumab for Locoregionally Advanced Nasopharyngeal Carcinoma: A Single-Arm, Phase II Trial2024International Journal of Radiation Oncology*Biology*Physicsarticle
  10. Significance of Longitudinal Epstein-Barr Virus DNA Combined with Tumor Response for Risk Stratification and Therapy Adaption in Nasopharyngeal Carcinoma2024International Journal of Radiation Oncology*Biology*Physicsarticle
  11. A Rare Case of EBV-positive Inflammatory Follicular Dendritic Cell Sarcoma of the Iliac Bone2023Research Squarepreprint
  12. CACA guidelines for holistic integrative management of nasopharyngeal carcinoma2023Holistic Integrative Oncologyarticle
  13. Combining Radiotherapy with Chemotherapy and Immunotherapy as First-Line Treatment for De Novo Metastatic Nasopharyngeal Carcinoma: A Dual-Center Retrospective Analysis2023International Journal of Radiation Oncology*Biology*Physicsarticle
  14. Investigating transfer learning to improve the deep-learning-based segmentation of organs at risk among different medical centers for nasopharyngeal carcinoma2023Frontiers in Physicsarticle
  15. More Efficient Auto-Segmentation Framework Using Patient-Specific Information for CBCT-Guided Adaptive Radiotherapy2023International Journal of Radiation Oncology*Biology*Physicsarticle
  16. Prediction of Anatomical Presentation during Radiotherapy of Nasopharyngeal Carcinoma Using GAN-LSTM for Plan Adaption Decision2023International Journal of Radiation Oncology*Biology*Physicsarticle
  17. Progress in the comprehensive treatment of nasopharyngeal carcinoma: a review for risk-stratified management strategies2023Holistic Integrative Oncologyarticle
  18. Prospective Efficacy of Two Cycles Toripalimab Plus Induction Chemotherapy in T4 or N3 Locoregionally Advanced Nasopharyngeal Carcinoma: A Retrospective and Mechanistic Study2023International Journal of Radiation Oncology*Biology*Physicsarticle
  19. The Short-Term Efficacy and Safety of Induction Chemotherapy Combined with PD-1 Inhibitor or Anti-EGFR in Locoregionally Advanced Nasopharyngeal Carcinoma2023International Journal of Radiation Oncology*Biology*Physicsarticle
  20. MRI-Identified Multidimensional Nodal Features: Predict Survival and Concurrent Chemotherapy Benefit for Stage II Nasopharyngeal Carcinoma2022International Journal of Radiation Oncology*Biology*Physicsarticle
  21. Potential Metastatic Distance of Lymph Nodes in Different Metastatic Patterns for Nasopharyngeal Carcinoma: Implications for Caudal Border of Elective Nodal Target Volume Delineation2022International Journal of Radiation Oncology*Biology*Physicsarticle
  22. Adjuvant capecitabine in locoregionally advanced nasopharyngeal carcinoma: A multicenter randomized controlled phase III trial.2021Journal of Clinical Oncologyconference-abstract
  23. Prognostic Significance of Tumor Infiltrating Lymphocytes (TILs) and Programmed Cell Death-Ligand 1 (PD-L1) in Nasopharyngeal Carcinoma2021International Journal of Radiation Oncology*Biology*Physicsarticle
  24. Stereotactic Body Radiation Therapy for the First-Line Comprehensive Treatment of Oligometastatic Nasopharyngeal Carcinoma: A Prospective, Single-Arm, Phase II Trial2021International Journal of Radiation Oncology*Biology*Physicsarticle

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 184 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 6.3%.

Papers led
184
2021–2025
Trials led
19
any status, ClinicalTrials.gov
Open trials led
10
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 424220212022: 333320222023: 373720232024: 333320242025: 37372025

12 hospitals in Beijing for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 13

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Radiotherapy Target Volume Delineation in Locally Advanced Esophageal Cancer in the Immunotherapy Era
    Phase
    Not given
    Started
    2026-08
    Registry
    NCT07858630

    Age 18 years to 80 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  2. Recruiting
    Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer
    Phase
    Phase 2
    Started
    2024-05
    Registry
    NCT06421376

    Age 18 years to 80 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMS; 2 listed hospitals as study sitesAnyang, Beijing, Xinxiang

  3. Recruiting
    Neoadjuvant Comprehensive Treatment for Unresectable Esophageal Cancer
    Phase
    Phase 2
    Started
    2024-04
    Registry
    NCT06430658

    Age 18 years to 75 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  4. Recruiting
    Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2023-03
    Registry
    NCT06410651

    Age 18 years to 80 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  5. Recruiting
    Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients
    Phase
    Phase 2
    Started
    2023-03
    Registry
    NCT06429839

    Age 18 years to 80 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  6. Recruiting
    Surgery or Chemoradiotherapy for Cervical Esophageal Cancer
    Phase
    N/A
    Started
    2022-04
    Registry
    NCT05327517

    Age 18 years to 75 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  7. Recruiting
    Chemoradiotherapy in Unresectable Esophageal Cancer
    Phase
    Phase 1/Phase 2
    Started
    2019-10
    Registry
    NCT04278287

    Age 18 years to 75 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMS; 4 listed hospitals as study sitesAnyang, Beijing, Changsha, Nanjing

  8. Not yet recruiting
    Total Neoadjuvant Therapy Combined With Adebrelimab in Locally Advanced Resectable ESCC
    Phase
    Phase 2/Phase 3
    Started
    2025-03
    Registry
    NCT06861777

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  9. Not yet recruiting
    Prognostic Analysis of Esophageal Cancer with Complete Pathological Response After Neoadjuvant Therapy
    Phase
    Not given
    Started
    2025-04
    Registry
    NCT06889402

    Age 18 years to 85 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  10. Enrolling by invitation
    A Multicenter Trial of YSQTG vs. Simulated Agents With Neoadjuvant Chemoradiotherapy or Chemoimmunotherapy for EC
    Phase
    N/A
    Started
    2024-08
    Registry
    NCT06863831

    Age 18 years to 80 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  11. Recruiting
    Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07733830

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & Hospital; 6 listed hospitals as study sitesBeijing, Chengdu, Shenyang, Taiyuan, Tianjin, Zhengzhou

  12. Recruiting
    KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07481058

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  13. Recruiting
    A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer
    Phase
    Phase 3
    Started
    2024-02
    Registry
    NCT06194734

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesMolecular markers & genomicsRadiotherapyNeoadjuvant & combined treatment
Departments in papersMedical oncologyRadiation oncologyPathology / laboratory medicineGastroenterology / hepatology
Papers it led184
  1. Clinofibrate Disrupts the SNORA80B/YTHDC1-Driven M6A Modification to Suppress Cholesterol Metabolism and Cisplatin Resistance in ESCC.2026Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  2. Simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal squamous cell carcinoma: A multicenter, open-label, randomized, phase III clinical trial.2026International journal of cancerRCT
  3. NKX2-5/LHX1 and UHRF1 Establishing a Positive Feedback Regulatory Circuitry Drives Esophageal Squamous Cell Carcinoma through Epigenetic Dysregulation.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  4. Hypoxia Induced Lnc191 Upregulation Dictates the Progression of Esophageal Squamous Cell Carcinoma by Activating GRP78/ERK Pathway.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  5. Risk of serum circulating environmental chemical residues to esophageal squamous cell carcinoma: a nested case-control metabolome-wide association study.2025Analytical and bioanalytical chemistry
  6. The predicting role of albumin to derived neutrophil-to-lymphocyte ratio for the prognosis of esophageal squamous cell carcinoma patients aged 60 years and above.2025BMC cancerFree full text
  7. Multi-modal radiomics features to predict overall survival of locally advanced esophageal cancer after definitive chemoradiotherapy.2025BMC cancerFree full text
  8. Definitive chemoradiotherapy combined with anti-PD-1 immunotherapy for inoperable esophageal squamous cell carcinoma: a multicenter real-world study.2025Cancer biology & therapyFree full text
  9. Single-cell multi-stage spatial evolutional map of esophageal carcinogenesis.2025Cancer cell
  10. Identification of an individualized immune-related miRNA pair signature for survival prediction of neoadjuvant chemoradiotherapy in esophageal squamous cell cancer.2025Cancer letters
  11. Characterization of novel mouse esophageal squamous cell carcinoma cell lines and their utility as preclinical models.2025Cancer letters
  12. Hypoxia-Induced Senescent Fibroblasts Secrete IGF1 to Promote Cancer Stemness in Esophageal Squamous Cell Carcinoma.2025Cancer research
  13. Unraveling the Oncogenic Characteristics of the Cytolinker, Plectin, in Esophageal Squamous Cell Carcinoma.2025Cellular and molecular gastroenterology and hepatologyFree full text
  14. Prognostic impact of recurrent laryngeal nerve lymph node metastatic status in thoracic esophageal squamous cell carcinoma.2025Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  15. Association between triclosan/triclocarban exposure and esophageal carcinoma development: A nested case-control study in a prospective cohort.2025Ecotoxicology and environmental safety
  16. Comparative Efficacy and Safety of Neoadjuvant Immunochemotherapy Versus Chemotherapy in Locally Advanced Oesophageal Squamous Cell Carcinoma: A Dual-Centre Retrospective Study.2025European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  17. Single-cell RNA sequencing and spatial transcriptomics of esophageal squamous cell carcinoma with lymph node metastases.2025Experimental & molecular medicineFree full text
  18. Genomic Instability is Widespread in Esophageal Squamous Dysplasia and Increases During the Progression to Cancer.2025Frontiers in bioscience (Landmark edition)
  19. LINC01605 Suppresses Esophageal Squamous Carcinogenesis by Regulating Squamous Cell Differentiation, Proliferation, and Migration.2025Frontiers in bioscience (Landmark edition)
  20. Whole grains temper immune-mediated inflammation in Chinese esophageal squamous-cell carcinoma survivors: a multicenter questionnaire study.2025Frontiers in immunologyFree full text
  21. Impact of consolidation immunotherapy after definitive chemoradiotherapy in locally advanced esophageal squamous cell carcinoma: a real-world multicenter study.2025International immunopharmacology
  22. Carboxymethyl cellulose/wheat gluten hydrogel engineered with core shell Co₃O₄@Au nanoparticles and toripalimab for local photodynamic-chemotherapy against esophageal squamous cell carcinoma.2025International journal of biological macromolecules
  23. Aberrant DNA Methylation in Esophageal Squamous Cell Carcinoma and its Clinical Implications in Systemic Chemotherapy.2025International journal of medical sciencesFree full text
  24. Neoadjuvant chemotherapy with albumin-bound paclitaxel plus cisplatin and capecitabine for locally advanced esophageal squamous cell carcinoma: a phase 2 clinical trial.2025International journal of surgery (London, England)Free full text
  25. Cadonilimab combined with taxane and cisplatin as the first-line treatment of advanced esophageal squamous cell carcinoma: an open-label, multicenter phase II trial.2025Journal for immunotherapy of cancerFree full text
  26. An effective multistage mouse model of esophageal carcinogenesis for preclinical and computational pathology applications.2025Neoplasia (New York, N.Y.)Free full text
  27. Efficacy and safety of concurrent programmed cell death protein 1 inhibitor and definitive radiotherapy with immunonutrition support in esophageal squamous cell cancer: a phase II multicenter clinical trial.2025Radiation oncology (London, England)Free full text
  28. A multidimensional deep ensemble learning model predicts pathological response and outcomes in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy from pretreatment CT imaging: A multicenter study.2025Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  29. Single-cell atlas of the esophageal squamous cell carcinoma immune ecosystem to predict immunotherapy response.2025Signal transduction and targeted therapyFree full text
  30. DNA/RNA-binding protein KIN17 supports esophageal cancer progression via resolving noncanonical STING activation induced by R-loop.2025Signal transduction and targeted therapyFree full text
  31. Aberrant Notch-signaling promotes tumor angiogenesis in esophageal squamous-cell carcinoma.2025Signal transduction and targeted therapyFree full text
  32. Feasibility and tolerability of anlotinib plus PD-1 blockades as rechallenge immunotherapy in previously treated advanced ESCC: a retrospective study.2025The oncologistFree full text
  33. Circulating Tumor DNA Dynamic Changes in Esophageal Squamous Cell Carcinoma Receiving Immunochemotherapy.2025Thoracic cancerFree full text
  34. Survival and Perioperative Outcomes After Addition of Immunotherapy to Neoadjuvant Chemoradiotherapy for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma.2025Thoracic cancerFree full text
  35. Exploring the Clinical Value of Perioperative ctDNA-Based Detection of Molecular Residual Disease in Patients With Esophageal Squamous Cell Carcinoma.2025Thoracic cancerFree full text
  36. Lymph Node Metastasis for pN+ Superficial Esophageal Squamous Cell Carcinoma.2025Thoracic cancerFree full text
  37. circ-TTC17 Promotes Esophagus Squamous Cell Carcinoma Cell Growth, Metastasis, and Inhibits Autophagy-Mediated Radiosensitivity Through miR-145-5p/SIRT1 Axis.2025Thoracic cancerFree full text
  38. Circ_0096710 facilitates tumor growth via controlling ADAM10 expression in esophageal squamous cell carcinoma.2025Thoracic cancerFree full text
  39. cfDNA hydroxymethylcytosine profiling for detection metastasis and recurrence of Esophageal Squamous Cell Carcinoma.2025World journal of surgical oncologyFree full text
  40. Bismuth Sulfide Nanoflowers Facilitated miR339 Delivery to Overcome Stemness and Radioresistance through Ubiquitin-Specific Peptidase 8 in Esophageal Cancer.2024ACS nano
  41. Targeting ABCA1 via Extracellular Vesicle-Encapsulated Staurosporine as a Therapeutic Strategy to Enhance Radiosensitivity.2024Advanced healthcare materials
  42. Octadecyl Gallate and Lipid-Modified MnSe2 Nanoparticles Enhance Radiosensitivity in Esophageal Squamous Cell Carcinoma and Promote Radioprotection in Normal Tissues.2024Advanced materials (Deerfield Beach, Fla.)
  43. Spatial Isoforms Reveal the Mechanisms of Metastasis.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  44. HLA-A+ tertiary lymphoid structures with reactivated tumor infiltrating lymphocytes are associated with a positive immunotherapy response in esophageal squamous cell carcinoma.2024British journal of cancerFree full text
  45. S-1-based concurrent chemoradiotherapy plus nimotuzumab in patients with locally advanced esophageal squamous cell carcinoma who failed neoadjuvant therapy: a real-world prospective study.2024Cancer biology & therapyFree full text
  46. HLX07 alone or combined with serplulimab, cisplatin and 5-fluorouracil for advanced esophageal squamous cell carcinoma: A phase 2 study.2024Cancer communications (London, England)Free full text
  47. Overactivation of XBP1 in plasma cells implies worse survival through innate immunity in esophageal squamous cell carcinoma.2024Cancer letters
  48. An effective two-stage NMBzA-induced rat esophageal tumor model revealing that the FAT-Hippo-YAP1 axis drives the progression of ESCC.2024Cancer letters
  49. JunD-miR494-CUL3 axis promotes radioresistance and metastasis by facilitating EMT and restraining PD-L1 degradation in esophageal squamous cell carcinoma.2024Cancer letters
  50. The effect of liver metastases on clinical efficacy of first-line programmed death-1 inhibitor plus chemotherapy in esophageal squamous cell carcinoma: A post hoc analysis of ASTRUM-007 and meta-analysis.2024Cancer medicineFree full text
  51. Alarmin S100A8 imparts chemoresistance of esophageal cancer by reprogramming cancer-associated fibroblasts.2024Cell reports. MedicineFree full text
  52. Somatic CDKN2A copy number variations are associated with the prognosis of esophageal squamous cell dysplasia.2024Chinese medical journalFree full text
  53. Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial.2024Clinical cancer research : an official journal of the American Association for Cancer Research
  54. Endoscopic submucosal dissection for early esophageal squamous cell carcinoma after ligation and sclerotherapy of esophageal and gastric varices.2024Clinics and research in hepatology and gastroenterology
  55. Time-dependent prognostic impact of circumferential resection margin in T3 thoracic esophageal squamous cell carcinoma.2024Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  56. KLF12 interacts with TRIM27 to affect cisplatin resistance and cancer metastasis in esophageal squamous cell carcinoma by regulating L1CAM expression.2024Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
  57. Enhancer demethylation-regulated gene score identified molecular subtypes, inspiring immunotherapy or CDK4/6 inhibitor therapy in oesophageal squamous cell carcinoma.2024EBioMedicineFree full text
  58. Antitumour effects of artesunate via cell cycle checkpoint controls in human oesophageal squamous carcinoma cells.2024European journal of medical researchFree full text
  59. Nuclear-cytoplasmic translocation of SQSTM1/p62 protein enhances ESCC cell migration and invasion by stabilizing EPLIN expression.2024Experimental cell research
  60. Tumor-Derived Exosomal miR-143-3p Induces Macrophage M2 Polarization to Cause Radiation Resistance in Locally Advanced Esophageal Squamous Cell Carcinoma.2024International journal of molecular sciencesFree full text
  61. Minimal residual disease profiling predicts pathological complete response in esophageal squamous cell carcinoma.2024Molecular cancerFree full text
  62. Single-cell sequencing reveals immune features of treatment response to neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma.2024Nature communicationsFree full text
  63. Multimodal analysis of cfDNA methylomes for early detecting esophageal squamous cell carcinoma and precancerous lesions.2024Nature communicationsFree full text
  64. Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial.2024Nature medicineRCTFree full text
  65. TMSB4Y restrains sphingomyelin synthesis via de novo purine synthesis to exert a tumor suppressor function in male esophageal squamous cell carcinoma.2024Oncogene
  66. Protocol to establish patient-derived xenograft and organoid for radiosensitivity of esophageal squamous cell carcinoma.2024STAR protocolsFree full text
  67. Novel DNA methylation markers for early detection of gastric cardia adenocarcinoma and esophageal squamous cell carcinoma.2024Science China. Life sciences
  68. Conversion chemoradiotherapy combined with nab-paclitaxel plus cisplatin in patients with locally advanced borderline-resectable or unresectable esophageal squamous cell carcinoma: a phase i/ii prospective cohort study.2024Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]Free full text
  69. Performance of Prediction Models for Esophageal Squamous Cell Carcinoma in General Population: A Systematic Review and External Validation Study.2024The American journal of gastroenterologyFree full text
  70. Neoadjuvant chemotherapy combined with immunotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma.2024The Journal of thoracic and cardiovascular surgery
  71. Identification of prognostic value of anoikis-related gene score model combined with tumor microenvironment score models in esophageal squamous cell carcinoma.2024The journal of gene medicine
  72. Exploration of the pattern of lymph node metastasis in esophageal cancer based on membrane anatomy theory.2024Thoracic cancerFree full text
  73. All-Trans Retinoic Acid Promotes a Tumor Suppressive OTUD6B-β-TrCP-SNAIL Axis in Esophageal Squamous Cell Carcinoma and Enhances Immunotherapy.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  74. The predicting role of serum tumor-specific growth factor for prognosis of esophageal squamous cell carcinoma.2023BMC cancerFree full text
  75. Prognostic significance of lymphovascular invasion in patients with pT1b esophageal squamous cell carcinoma.2023BMC cancerFree full text
  76. Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial : A randomized clinical trial of neoadjuvant therapy for ESCC.2023BMC medicineRCTFree full text
  77. Gelatin-based 3D biomimetic scaffolds platform potentiates culture of cancer stem cells in esophageal squamous cell carcinoma.2023Biomaterials
  78. Genomic alterations driving precancerous to cancerous lesions in esophageal cancer development.2023Cancer cell
  79. Integrated multi-omics profiling yields a clinically relevant molecular classification for esophageal squamous cell carcinoma.2023Cancer cell
  80. Mutant p53 activates hnRNPA2B1-AGAP1-mediated exosome formation to promote esophageal squamous cell carcinoma progression.2023Cancer letters
  81. MARCKSL1 interacted with F-actin to promote esophageal squamous cell carcinoma mobility by modulating the formation of invadopodia.2023Cancer medicineFree full text
  82. BACH1-induced ferroptosis drives lymphatic metastasis by repressing the biosynthesis of monounsaturated fatty acids.2023Cell death & diseaseFree full text
  83. m6A demethylase FTO stabilizes LINK-A to exert oncogenic roles via MCM3-mediated cell-cycle progression and HIF-1α activation.2023Cell reports
  84. Collagen 1-mediated CXCL1 secretion in tumor cells activates fibroblasts to promote radioresistance of esophageal cancer.2023Cell reports
  85. Mammalian esophageal stratified tissue homeostasis is maintained distinctively by the epithelial pluripotent p63+Sox2+ and p63-Sox2+ cell populations.2023Cellular and molecular life sciences : CMLSFree full text
  86. Microbial and epidemiological factors in early detection of esophageal squamous cell carcinoma and precancerous lesions.2023Chinese medical journalFree full text
  87. Endoscopic Surveillance for Premalignant Esophageal Lesions: A Community-Based Multicenter, Prospective Cohort Study.2023Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  88. Efficacy and Safety of Concurrent Chemoradiotherapy Combined with Nimotuzumab in Elderly Patients with Esophageal Squamous Cell Carcinoma: A Prospective Real-world Pragmatic Study.2023Current cancer drug targets
  89. DNA damage repair profiling of esophageal squamous cell carcinoma uncovers clinically relevant molecular subtypes with distinct prognoses and therapeutic vulnerabilities.2023EBioMedicineFree full text
  90. GDF15 negatively regulates chemosensitivity via TGFBR2-AKT pathway-dependent metabolism in esophageal squamous cell carcinoma.2023Frontiers of medicine
  91. A-to-I RNA-Editing: An Epigenetic Hallmark Cannot Be Ignored in Silencing the Tumor Microenvironment and Is Promising in Predicting Immunotherapy Response for Esophageal Squamous Cell Carcinoma.2023Gastroenterology
  92. Comprehensive Analyses Reveal Effects on Tumor Immune Infiltration and Immunotherapy Response of APOBEC Mutagenesis and Its Molecular Mechanisms in Esophageal Squamous Cell Carcinoma.2023International journal of biological sciencesFree full text
  93. Effectiveness of S-1-Based Chemoradiotherapy in Patients 70 Years and Older With Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.2023JAMA network openRCTFree full text
  94. Hypoxia-induced TMTC3 expression in esophageal squamous cell carcinoma potentiates tumor angiogenesis through Rho GTPase/STAT3/VEGFA pathway.2023Journal of experimental & clinical cancer research : CRFree full text
  95. HCP5 prevents ubiquitination-mediated UTP3 degradation to inhibit apoptosis by activating c-Myc transcriptional activity.2023Molecular therapy : the journal of the American Society of Gene TherapyFree full text
  96. The transcriptional landscape and diagnostic potential of long non-coding RNAs in esophageal squamous cell carcinoma.2023Nature communicationsFree full text
  97. First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial.2023Nature medicineRCTFree full text
  98. FBXW7 inhibits the progression of ESCC by directly inhibiting the stemness of tumor cells.2023Neoplasma
  99. Single-cell RNA-sequencing data reveals the genetic source of extracellular vesicles in esophageal squamous cell carcinoma.2023Pharmacological research
  100. Aberrant epithelial cell interaction promotes esophageal squamous-cell carcinoma development and progression.2023Signal transduction and targeted therapyFree full text
  101. RPS15 interacted with IGF2BP1 to promote esophageal squamous cell carcinoma development via recognizing m6A modification.2023Signal transduction and targeted therapyFree full text
  102. Tumor-derived miR-20b-5p promotes lymphatic metastasis of esophageal squamous cell carcinoma by remodeling the tumor microenvironment.2023Signal transduction and targeted therapyFree full text
  103. The efficacy of additional surgical resection after endoscopic resection in pT1b esophageal squamous cell carcinoma: A multi-institutional retrospective study in China.2023Surgical endoscopyFree full text
  104. Radiotherapy Improves Survival of Patients With Lymphovascular Invasion in pT1b Esophageal Squamous Cell Cancer After Endoscopic Submucosal Dissection.2023The American journal of gastroenterology
  105. Integrated molecular characterization of esophageal basaloid squamous cell carcinoma: a subtype with distinct RNA expression pattern and immune characteristics, but no specific genetic mutations.2023The Journal of pathology
  106. Tumor budding and tumor-infiltrating lymphocytes can predict prognosis in pT1b esophageal squamous cell carcinoma.2023Thoracic cancerFree full text
  107. The efficacy and safety of nanoparticle albumin bound-paclitaxel-based regimen as second- or third-line treatment in patients with advanced esophageal squamous cell carcinoma.2023Thoracic cancerRCTFree full text
  108. Comparison of neoadjuvant nab-paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma.2023Thoracic cancerFree full text
  109. Comparison of the Clinicopathological Characteristics and Prognosis of Esophageal Squamous Cell Carcinoma with Intramural Metastases and Multiple Primary Carcinomas.2023World journal of surgery
  110. The prognostic significance of the circumferential resection margin in esophageal squamous cell carcinoma patients without neoadjuvant treatment.2022BMC cancerFree full text
  111. Dietary patterns and severity of symptom with the risk of esophageal squamous cell carcinoma and its histological precursor lesions in China: a multicenter cross-sectional latent class analysis.2022BMC cancerFree full text
  112. GINS4 might be a novel prognostic immune-related biomarker of not only esophageal squamous cell carcinoma and other cancers.2022BMC medical genomicsFree full text
  113. Dysregulation of CXCL14 promotes malignant phenotypes of esophageal squamous carcinoma cells via regulating SRC and EGFR signaling.2022Biochemical and biophysical research communications
  114. A liquid biopsy signature predicts lymph node metastases in T1 oesophageal squamous cell carcinoma: implications for precision treatment strategy.2022British journal of cancerFree full text
  115. Disruption of enhancer-driven S100A14 expression promotes esophageal carcinogenesis.2022Cancer letters
  116. Feasibility of using P16 methylation as a cytologic marker for esophageal squamous cell carcinoma screening: A pilot study.2022Cancer medicineFree full text
  117. Computational Identification of Preneoplastic Cells Displaying High Stemness and Risk of Cancer Progression.2022Cancer research
  118. Prognostic value of circulating tumour DNA during post-radiotherapy surveillance in locally advanced esophageal squamous cell carcinoma.2022Clinical and translational medicineFree full text
  119. Lipid metabolism-related lncRNA SLC25A21-AS1 promotes the progression of oesophageal squamous cell carcinoma by regulating the NPM1/c-Myc axis and SLC25A21 expression.2022Clinical and translational medicineFree full text
  120. Integrating microarray-based spatial transcriptomics and single-cell RNA-sequencing reveals tissue architecture in esophageal squamous cell carcinoma.2022EBioMedicineFree full text
  121. Factors affecting the completion of concurrent chemotherapy and impact of non-completion on survival in locally advanced esophageal squamous cell carcinoma.2022Esophagus : official journal of the Japan Esophageal Society
  122. MAFB promotes the malignant phenotypes by IGFBP6 in esophageal squamous cell carcinomas.2022Experimental cell research
  123. Caspase-8 mutants activate Nrf2 via phosphorylating SQSTM1 to protect against oxidative stress in esophageal squamous cell carcinoma.2022Free radical biology & medicine
  124. Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma.2022Frontiers in immunologyFree full text
  125. The Deubiquitinase USP39 Promotes Esophageal Squamous Cell Carcinoma Malignancy as a Splicing Factor.2022GenesFree full text
  126. Combined risk factors and risk of upper gastrointestinal cancer mortality in the Linxian general population.2022International journal of cancer
  127. Global and national trends in the age-specific sex ratio of esophageal cancer and gastric cancer by subtype.2022International journal of cancerFree full text
  128. Long-term Incidence Rates of Esophageal Squamous Cell Carcinoma in Chinese Patients With Low-grade Intraepithelial Neoplasia and Association of Surveillance Endoscopy With Incidence.2022JAMA network openFree full text
  129. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity score-matched study from the National Cancer Center in China.2022Journal of cancer research and clinical oncologyFree full text
  130. SLC35E2 promoter mutation as a prognostic marker of esophageal squamous cell carcinoma.2022Life sciences
  131. Intensity modulated radiotherapy might be effective for locally advanced esophageal carcinosarcoma: A single center's experience and review of literature.2022MedicineFree full text
  132. Forming cytoplasmic stress granules PURα suppresses mRNA translation initiation of IGFBP3 to promote esophageal squamous cell carcinoma progression.2022OncogeneFree full text
  133. Dysregulated ceramides metabolism by fatty acid 2-hydroxylase exposes a metabolic vulnerability to target cancer metastasis.2022Signal transduction and targeted therapyFree full text
  134. A cis-eQTL in NSUN2 promotes esophageal squamous-cell carcinoma progression and radiochemotherapy resistance by mRNA-m5C methylation.2022Signal transduction and targeted therapyFree full text
  135. Molecular characteristics of multifocal esophageal squamous cell carcinomas to discriminate multicentric origin from intramural metastasis.2022The Journal of pathology
  136. Clinical significance of left tracheobronchial lymph node dissection in thoracic esophageal squamous cell carcinoma.2022The Journal of thoracic and cardiovascular surgery
  137. Is it necessary for patients with potentially resectable esophageal squamous cell cancer to receive routine preoperative brain MRI/CT?2022Thoracic cancerFree full text
  138. 99m Tc bone scintigraphy does not affect preoperative workup for patients with potentially resectable esophageal squamous cell carcinoma.2022Thoracic cancerFree full text
  139. Modified Glasgow prognostic score predicts the prognosis of patients with advanced esophageal squamous cell carcinoma: A propensity score-matched analysis.2022Thoracic cancerFree full text
  140. Prognostic and predictive impact of neutrophil-to-lymphocyte ratio and HLA-I genotyping in advanced esophageal squamous cell carcinoma patients receiving immune checkpoint inhibitor monotherapy.2022Thoracic cancerFree full text
  141. Neoadjuvant chemotherapy with liposomal paclitaxel plus platinum for locally advanced esophageal squamous cell cancer: Results from a retrospective study.2022Thoracic cancerFree full text
  142. NEFL promotes invasion and migration of esophageal squamous carcinoma cells via the EGFR/AKT/S6 pathway.2022Yi chuan = Hereditas
  143. Clinical practice and outcome of radiotherapy for advanced esophageal squamous cell carcinoma between 2002 and 2018 in China: the multi-center 3JECROG Survey.2021Acta oncologica (Stockholm, Sweden)
  144. OTUD1 Activates Caspase-Independent and Caspase-Dependent Apoptosis by Promoting AIF Nuclear Translocation and MCL1 Degradation.2021Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  145. Comparison of Two Major Staging Systems in Predicting Survival and Recommendation of Postoperative Radiotherapy Based on the 11th Japanese Classification for Esophageal Carcinoma After Curative Resection: A Propensity Score-Matched Analysis2021Annals of surgical oncology
  146. Risk factors for esophageal squamous cell carcinoma and its histological precursor lesions in China: a multicenter cross-sectional study.2021BMC cancerFree full text
  147. Aspirin enhances the therapeutic efficacy of cisplatin in oesophageal squamous cell carcinoma by inhibition of putative cancer stem cells.2021British journal of cancerFree full text
  148. Gastroesophageal reflux disease: A risk factor for laryngeal squamous cell carcinoma and esophageal squamous cell carcinoma in the NIH-AARP Diet and Health Study cohort.2021CancerFree full text
  149. Phase I study of liposomal irinotecan (LY01610) in patients with advanced esophageal squamous cell carcinoma.2021Cancer chemotherapy and pharmacologyFree full text
  150. Improved esophageal squamous cell carcinoma screening effectiveness by risk-stratified endoscopic screening: evidence from high-risk areas in China.2021Cancer communications (London, England)Free full text
  151. Liquid biopsy for esophageal cancer: Is detection of circulating cell-free DNA as a biomarker feasible?2021Cancer communications (London, England)Free full text
  152. Multi-region sequencing reveals genetic correlation between esophageal squamous cell carcinoma and matched cell-free DNA.2021Cancer genetics
  153. PURα mediates epithelial-mesenchymal transition to promote esophageal squamous cell carcinoma progression by regulating Snail2.2021Cancer letters
  154. BACH1 promotes the progression of esophageal squamous cell carcinoma by inducing the epithelial-mesenchymal transition and angiogenesis.2021Cancer medicineFree full text
  155. Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double-blind randomized phase 2 trial.2021Cancer medicineRCTFree full text
  156. CstF64-Induced Shortening of the BID 3'UTR Promotes Esophageal Squamous Cell Carcinoma Progression by Disrupting ceRNA Cross-talk with ZFP36L2.2021Cancer research
  157. Long Noncoding RNA VESTAR Regulates Lymphangiogenesis and Lymph Node Metastasis of Esophageal Squamous Cell Carcinoma by Enhancing VEGFC mRNA Stability.2021Cancer research
  158. A GRN Autocrine-Dependent FAM135B/AKT/mTOR Feedforward Loop Promotes Esophageal Squamous Cell Carcinoma Progression.2021Cancer research
  159. miR-4306 Suppresses Proliferation of Esophageal Squamous Cell Carcinoma Cell by Targeting SIX3.2021Cell biochemistry and biophysics
  160. TGF-β-induced PLEK2 promotes metastasis and chemoresistance in oesophageal squamous cell carcinoma by regulating LCN2.2021Cell death & diseaseFree full text
  161. The oncogenomic function of androgen receptor in esophageal squamous cell carcinoma is directed by GATA3.2021Cell researchFree full text
  162. Programmed cell death ligand 1 expression in esophageal squamous cell carcinoma: a comparative analysis of three different assays.2021Chinese medical journalFree full text
  163. S100A7 as a potential diagnostic and prognostic biomarker of esophageal squamous cell carcinoma promotes M2 macrophage infiltration and angiogenesis.2021Clinical and translational medicineFree full text
  164. Esophageal squamous cell carcinoma or high-grade dysplasia overlying leiomyoma, rare but not to be neglected.2021Esophagus : official journal of the Japan Esophageal Society
  165. Characterization of the Oral and Esophageal Microbiota in Esophageal Precancerous Lesions and Squamous Cell Carcinoma.2021Frontiers in cellular and infection microbiologyFree full text
  166. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.2021Frontiers in immunologyFree full text
  167. An initial screening strategy based on epidemiologic information in esophageal cancer screening: a prospective evaluation in a community-based cancer screening cohort in rural China.2021Gastrointestinal endoscopy
  168. Selection of high-risk individuals for esophageal cancer screening: A prediction model of esophageal squamous cell carcinoma based on a multicenter screening cohort in rural China.2021International journal of cancer
  169. Elevated serum eotaxin and IP-10 levels as potential biomarkers for the detection of esophageal squamous cell carcinoma.2021Journal of clinical laboratory analysisFree full text
  170. Extracellular vesicles derived from oesophageal cancer containing P4HB promote muscle wasting via regulating PHGDH/Bcl-2/caspase-3 pathway.2021Journal of extracellular vesiclesFree full text
  171. Remarkable inhibition effects of afatinib alone or combining with paclitaxel in esophageal squamous cell carcinoma.2021Journal of gastroenterology and hepatology
  172. LAMC1 upregulation via TGFβ induces inflammatory cancer-associated fibroblasts in esophageal squamous cell carcinoma via NF-κB-CXCL1-STAT3.2021Molecular oncologyFree full text
  173. Dissecting esophageal squamous-cell carcinoma ecosystem by single-cell transcriptomic analysis.2021Nature communicationsFree full text
  174. METTL3 promotes tumour development by decreasing APC expression mediated by APC mRNA N6-methyladenosine-dependent YTHDF binding.2021Nature communicationsFree full text
  175. Multi-omics profiling of primary small cell carcinoma of the esophagus reveals RB1 disruption and additional molecular subtypes.2021Nature communicationsFree full text
  176. The landscape and biological relevance of aberrant alternative splicing events in esophageal squamous cell carcinoma.2021Oncogene
  177. Phosphoproteomics reveals therapeutic targets of esophageal squamous cell carcinoma.2021Signal transduction and targeted therapyFree full text
  178. VAV2 is required for DNA repair and implicated in cancer radiotherapy resistance.2021Signal transduction and targeted therapyFree full text
  179. Adjuvant immunotherapy in resected esophageal squamous cell carcinoma: a gospel to the non-pCRs.2021Signal transduction and targeted therapyFree full text
  180. Additional Radiotherapy With or Without Chemotherapy Following Endoscopic Resection for Stage I Esophageal Carcinoma: A Pilot Study.2021Technology in cancer research & treatmentFree full text
  181. Population Attributable Risks of Subtypes of Esophageal and Gastric Cancers in the United States.2021The American journal of gastroenterologyFree full text
  182. Postoperative Adjuvant Therapy Versus Surgery Alone for Stage IIB-III Esophageal Squamous Cell Carcinoma: A Phase III Randomized Controlled Trial.2021The oncologistRCTFree full text
  183. Concurrent chemoradiotherapy versus radiotherapy alone for patients with locally advanced esophageal squamous cell carcinoma in the era of intensity modulated radiotherapy: a propensity score-matched analysis.2021Thoracic cancerFree full text
  184. SHR-1316, an anti-PD-L1 antibody, plus chemotherapy as the first-line treatment for advanced esophageal squamous cell carcinoma: A multicentre, phase 2 study.2021Thoracic cancerFree full text
Chinese-language papers (not in the count)15
  1. [Status and prospect of esophageal cancer screening].2025Zhonghua zhong liu za zhi [Chinese journal of oncology]
  2. [Development and validation of predictive models for esophageal squamous cell carcinoma and its precancerous lesions using terminal motif analysis in circulating cell-free DNA].2024Zhonghua zhong liu za zhi [Chinese journal of oncology]
  3. [En1 promotes cell proliferation and migration via Hedgehog signaling pathway in esophageal squamous cell carcinoma].2024Zhonghua zhong liu za zhi [Chinese journal of oncology]
  4. [Application of novel non-endoscopic device in the screening and early diagnosis of esophageal cancer].2023Zhonghua zhong liu za zhi [Chinese journal of oncology]
  5. [Characteristics of lymph node metastasis of right recurrent laryngeal nerve in thoracic esophageal squamous cell carcinoma].2023Zhonghua zhong liu za zhi [Chinese journal of oncology]
  6. [Clinical analysis of liver dysfunction induced by SHR-1210 alone or combined with apatinib and chemotherapy in patients with advanced esophageal squamous cell carcinoma].2023Zhonghua zhong liu za zhi [Chinese journal of oncology]
  7. [Analysis of risk factors for depth of invasion and angiolymphatic invasion for circumferential superficial esophageal squamous cell carcinoma and precancerous lesion].2023Zhonghua zhong liu za zhi [Chinese journal of oncology]
  8. [Oligometastatic and oligoprogressive esophageal squamous cell carcinoma:clarifying conceptions and surgery perspectives].2022Zhonghua wai ke za zhi [Chinese journal of surgery]
  9. [Clinical characteristics of digestive system cancers metastatic to the heart].2022Zhonghua zhong liu za zhi [Chinese journal of oncology]
  10. [MIR503HG promotes esophageal squamous cell carcinoma cell proliferation, invasion and migration via hsa-miR-503 pathway].2022Zhonghua zhong liu za zhi [Chinese journal of oncology]
  11. [Establishment and clinical validation of an artificial intelligence YOLOv51 model for the detection of precancerous lesions and superficial esophageal cancer in endoscopic procedure].2022Zhonghua zhong liu za zhi [Chinese journal of oncology]
  12. [Progress in risk factors and potential biomarkers of esophageal squamous cell carcinoma].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
  13. [Correlation between nUGT1A1 gene polymorphisms and adverse events of irinotecan plus S-1 for patients with recurrent or metastatic esophageal squamous cell carcinoma: a prospective, open-label, randomized controlled trial (ESWN 01)].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]RCT
  14. [Long-term efficacy and safety of simultaneous integrated boost radiotherapy in non-operative esophageal squamous cell carcinoma: a multicenter retrospective data analysis (3JECROG R-05)].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
  15. [SERPINE2 promotes cellular migration and invasion in esophageal squamous cell carcinoma by activating β-catenin].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
All its trials on ClinicalTrials.gov, any status33
  1. Radiotherapy Target Volume Delineation in Locally Advanced Esophageal Cancer in the Immunotherapy EraRecruitingNCT07858630Lead (inferred)Start 2026-08
  2. Total Neoadjuvant Therapy Combined With Adebrelimab in Locally Advanced Resectable ESCCNot yet recruitingNCT06861777Lead (inferred)Phase 2/Phase 3Start 2025-03
  3. Prognostic Analysis of Esophageal Cancer with Complete Pathological Response After Neoadjuvant TherapyNot yet recruitingNCT06889402Lead (inferred)Start 2025-04
  4. Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal CancerRecruitingNCT06421376Lead (inferred)Phase 2Start 2024-05
  5. Neoadjuvant Comprehensive Treatment for Unresectable Esophageal CancerRecruitingNCT06430658Lead (inferred)Phase 2Start 2024-04
  6. A Multicenter Trial of YSQTG vs. Simulated Agents With Neoadjuvant Chemoradiotherapy or Chemoimmunotherapy for ECEnrolling by invitationNCT06863831Lead (inferred)N/AStart 2024-08
  7. Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell CarcinomaRecruitingNCT06410651Lead (inferred)Phase 2Start 2023-03
  8. Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer PatientsRecruitingNCT06429839Lead (inferred)Phase 2Start 2023-03
  9. Surgery or Chemoradiotherapy for Cervical Esophageal CancerRecruitingNCT05327517Lead (inferred)N/AStart 2022-04
  10. Chemoradiotherapy in Unresectable Esophageal CancerRecruitingNCT04278287Lead (inferred)Phase 1/Phase 2Start 2019-10
  11. Phase II Study of Induction Chemoimmunotherapy Followed by Radiotherapy and Organ Preservation in Resectable ESCCActive, not recruitingNCT07711470Lead (inferred)Phase 2Start 2026-07
  12. Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal JunctionStatus unknownNCT05865132Lead (inferred)Phase 2Start 2023-04
  13. Additional Consolidative Esophagectomy for the Patients With Oligometastatic Resectable ESCCActive, not recruitingNCT05951127Lead (inferred)N/AStart 2022-11
  14. Radiotherapy Plus Durvalumab in Elderly Esophageal Squamous Cell CarcinomaStatus unknownNCT04851132Lead (inferred)N/AStart 2021-03
  15. Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal CancerCompletedNCT04821765Lead (inferred)Phase 2Start 2020-10
  16. Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaStatus unknownNCT04390958Lead (inferred)Phase 2Start 2020-05
  17. Concurrent Chemoradiotherapy After Endoscopic Resection for Stage I Esophageal CarcinomaStatus unknownNCT04275986Lead (inferred)Phase 2Start 2020-01
  18. A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal CancerCompletedNCT04207918Lead (inferred)Phase 2Start 2019-11
  19. Radiotherapy Target Volume in Locally Advanced Esophageal Squamous Cell Carcinoma in the Immunotherapy EraActive, not recruitingNCT07879898Lead (inferred)Start 2018-01
  20. Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCCRecruitingNCT07733830Study sitePhase 2Start 2026-07
  21. KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal CancerRecruitingNCT07481058Study sitePhase 2Start 2025-12
  22. A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal CancerRecruitingNCT06194734Study sitePhase 3Start 2024-02
  23. JAB-3068 Activity in Adult Patients With Advanced Solid TumorsCompletedNCT04721223Study sitePhase 1/Phase 2Start 2021-04
  24. A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent ChemoradiotherapyCompletedNCT04543617Study sitePhase 3Start 2020-09
  25. A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in ChinaCompletedNCT04121286Study sitePhase 1Start 2020-07
  26. A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell CarcinomaCompletedNCT03957590Study sitePhase 3Start 2019-06
  27. A Clinical Trial Comparing HLX10 With Placebo Combined With Chemotherapy (Cisplatin + 5-fu) in the First-line Treatment of Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ESCC)Status unknownNCT03958890Study sitePhase 3Start 2019-06
  28. A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in ChinaCompletedNCT03565003Study sitePhase 1/Phase 2Start 2018-11
  29. PET in Guiding Cervical Lymphadenectomy (ECTOP-2003)CompletedNCT03244566Study siteStart 2018-06
  30. A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell CarcinomaStatus unknownNCT02409186Study sitePhase 3Start 2015-03
  31. Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell CarcinomaStatus unknownNCT02611700Study sitePhase 3Start 2015-11
  32. Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT01232374Study sitePhase 2Start 2010-09
  33. A Clinical Trial of a Radiation Sensitizer in Radiochemotherapy for Thoracic Esophageal Squamous CarcinomaStatus unknownNCT00642239Study sitePhase 4Start 2008-04
More papers found outside PubMed (not counted)57
  1. 1570P A phase I clinical trial of 5T4-antibody NK cell conjugation (IBR854 Injection) in patients with advanced solid tumor2025Annals of Oncologyarticle
  2. 271O Final analysis and biomarker evaluation of JUPITER-06: A phase III trial of toripalimab plus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma2025Annals of Oncologyarticle
  3. 305P Safety and efficacy of endoscopic resection followed by adjuvant chemoradiotherapy (ERACT) for organ preservation in early-stage oesophageal squamous cell carcinoma with high-risk features: A prospective, multicenter, phase II clinical2025Annals of Oncologyarticle
  4. 349. PATHOLOGIC COMPLETE RESPONSE IN ESOPHAGEAL SQUAMOUS CELL CANCER: DO DIVERSE NEOADJUVANT MODALITIES PREDICT PROGNOSTIC DIFFERENCES?2025Diseases of the Esophagusarticle
  5. 396P Overexpression of CKS1B in tumor causes CD8+ T cell exhaustion via persistent tumor-antigen stimulation and impaired immune selection2025Immuno-Oncology Technologyarticle
  6. A Multi-Dimensional Deep Ensemble Learning Model Predicts Pathological Response and Treatment Outcomes to Neoadjuvant Chemoradiotherapy in Esophageal Squamous Cell Carcinoma Using Pretreatment CT Images: A Multicenter, Retrospective Cohort 2025International Journal of Radiation Oncology*Biology*Physicsarticle
  7. Abstract 1945: High-sensitive gastrointestinal cancers early detection by cell-free DNA targeted methylation sequencing with an innovative modeling approach2025Cancer Researchconference-abstract
  8. An organ-preserving strategy in patients with esophageal squamous cell carcinoma treated with immunochemotherapy.2025Journal of Clinical Oncologyconference-abstract
  9. Efficacy, safety and DNA methylation analysis of cadonilimab combined with taxane and cisplatin as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): Updated results from an open-label, multicenter phase II trial (2025Journal of Clinical Oncologyconference-abstract
  10. PT2.10.03 Safety, Tolerability and Preliminary Efficacy of Anti-PD-L1 ADC HLX43 in Advanced/Metastatic Solid Tumors: A Phase I Study2025Journal of Thoracic Oncologyarticle
  11. Preliminary results of the ALTER-E009 study: Efficacy and safety of anlotinib combined with radiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC)—A multicenter, multi-cohort retrospective exp2025Journal of Clinical Oncologyconference-abstract
  12. The lost evidence: A phase III, multicenter randomized controlled trial of neoadjuvant chemotherapy paclitaxel plus cisplatin versus surgery alone for stage IIA–IIIB esophageal squamous cell carcinoma.2025Journal of Clinical Oncologyconference-abstract
  13. Updated results of the ALTER-E00 study: Efficacy and safety of anlotinib combined with radiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC): A multi-center, multi-cohort retrospective explor2025Journal of Clinical Oncologyarticle
  14. 179P Personalized minimal residual disease profiling predicts prognosis in esophageal carcinoma undergoing definitive radiotherapy2024Annals of Oncologyarticle
  15. 502P A novel miRNA pair biomarker of miR-1180-3p|miR-505-3p for predicting neoadjuvant chemoradiotherapy survival in esophageal squamous cell carcinoma: A multicenter study in China2024Annals of Oncologyarticle
  16. AN0025 in combination with definitive chemoradiotherapy (dCRT) in unresectable locally advanced or locally recurrent esophageal cancer (EC): A single-arm, open-label, multicenter, phase Ib study.2024Journal of Clinical Oncologyconference-abstract
  17. Abstract 2010: TRIM27 Interacts with KLF12 to regulate L1CAM expression, influencing cisplatin resistance and cancer metastasis in esophageal squamous cell carcinoma2024Cancer Researchconference-abstract
  18. Chemotherapy plus camrelizumab versus chemotherapy alone as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (ESCORT-NEO): A multi-center, randomized phase III trial.2024Journal of Clinical Oncologyconference-abstract
  19. Efficacy and Safety of the Combination of Tislelizumab with Chemoradiotherapy in Oligorecurrence Esophageal Squamous Cell Carcinoma: A Prospective Phase II Study2024International Journal of Radiation Oncology*Biology*Physicsarticle
  20. Efficacy and safety of the combination of tisleizumab with chemoradiotherapy in oligorecurrence esophageal squamous cell carcinoma: A prospective phase II study.2024Journal of Clinical Oncologyconference-abstract
  21. Efficacy, safety and DNA methylation analysis of cadonilimab combined with taxane and cisplatin as the first-line treatment in patients with advanced esophageal squamous cell carcinoma (ESCC): An open-label, multicenter phase II trial– Upda2024Journal of Clinical Oncologyconference-abstract
  22. Multimodality Deep Learning Radiomics Predicts Pathological Complete Response of Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy2024International Journal of Radiation Oncology*Biology*Physicsarticle
  23. Neoadjuvant Immunotherapy combined with Chemoradiotherapy VS. Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma(cStageII-III): Study Protocol For A Multi-center Prospective Randomized Clinical Trial2024Research Squarepreprint
  24. Neoadjuvant chemotherapy with albumin-bound paclitaxel plus cisplatin and capecitabine for locally advanced esophageal squamous cell carcinoma: A prospective phase II trial.2024Journal of Clinical Oncologyconference-abstract
  25. Radiotherapy Combined with Chemoimmunotherapy vs. Chemoimmunotherapy Alone as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma with Oligometastasis at Initial Diagnosis2024International Journal of Radiation Oncology*Biology*Physicsarticle
  26. Right vs Left Thoracic Approach for Esophageal Adenocarcinoma2024Difficult decisions in surgery: an evidence-based approachbook-chapter
  27. The feasibility and tolerability of anlotinib plus PD-1 blockades among patients with previously immunotherapy treated advanced esophageal squamous cell carcinoma (ESCC): Update results of a retrospective exploratory study.2024Journal of Clinical Oncologyconference-abstract
  28. “Pacific” Modality in Locally Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Analysis of a Real-World Multicenter Study2024International Journal of Radiation Oncology*Biology*Physicsarticle
  29. A phase 2 study of HLX07 as monotherapy or combination therapy in patients with locally advanced, unresectable, or metastatic esophageal squamous cell carcinoma.2023Journal of Clinical Oncologyconference-abstract
  30. Abstract 2594: Alcohol drinking inhibits NOTCH-PAX9 signaling in esophageal squamous epithelial cells2023Cancer Researchconference-abstract
  31. Chemoradiotherapy Combined with Nab-Paclitaxel plus Cisplatin in Patients with Locally Advanced Borderline Resectable or Unresectable Esophageal Squamous Cell Carcinoma: A Phase I/II Study2023International Journal of Radiation Oncology*Biology*Physicsarticle
  32. Data from Computational Identification of Preneoplastic Cells Displaying High Stemness and Risk of Cancer Progression2023Venue not listedother
  33. Data from Computational Identification of Preneoplastic Cells Displaying High Stemness and Risk of Cancer Progression2023Venue not listedother
  34. Data from CstF64-Induced Shortening of the BID 3′UTR Promotes Esophageal Squamous Cell Carcinoma Progression by Disrupting ceRNA Cross-talk with ZFP36L22023Venue not listedother
  35. Data from CstF64-Induced Shortening of the BID 3′UTR Promotes Esophageal Squamous Cell Carcinoma Progression by Disrupting ceRNA Cross-talk with ZFP36L22023Venue not listedother
  36. Identification of lymphophilic subtype in resectable esophageal squamous cell carcinoma using genetic signatures from large-scale genomic repertoires2023Research Squarepreprint
  37. KC1036, a novel oral multi-kinase inhibitor, in patients with previously treated advanced esophageal squamous cell carcinoma (ESCC): Results from a multicenter, single-arm phase II trial.2023Journal of Clinical Oncologyconference-abstract
  38. P-162 Preliminary results of the feasibility and tolerability of anlotinib plus PD-1 blockades among patients with previously immunotherapy treated advanced esophageal squamous cell carcinoma (ESCC): A retrospective exploratory study2023Annals of Oncologyconference-abstract
  39. Updated results of first-line serplulimab versus placebo plus chemotherapy in PD-L1–positive esophageal squamous cell carcinoma: A randomized, double-blind, multicenter phase 3 study (ASTRUM-007).2023Journal of Clinical Oncologyconference-abstract
  40. 121TiP Prospective, single arm, phase II clinical trial of pembrolizumab combined with neoadjuvant chemoradiotherapy and surgery for locally advanced upper esophageal squamous cell carcinoma2022Immuno-Oncology Technologyarticle
  41. 92P Neoadjuvant multimodality RX including immunotherapy for highly selective unresectable locally advanced esophageal squamous cell carcinoma (NEXUS): A prospective, single-arm, phase II trial2022Immuno-Oncology Technologyarticle
  42. A phase 3 randomized, double-blind, placebo-controlled, multicenter, global study of durvalumab with and after chemoradiotherapy in patients with locally advanced, unresectable esophageal squamous cell carcinoma: KUNLUN.2022Journal of Clinical Oncologyconference-abstract
  43. Effectiveness of S-1–Based Chemoradiotherapy and S-1 Consolidation in Elderly Patients with Esophageal Squamous Cell Carcinoma: A Multicenter Randomized Phase III Clinical Trial2022International Journal of Radiation Oncology*Biology*Physicsarticle
  44. Elevated Expression of The RNA-Binding Protein IGF2BP1 Enhances The Mrna Stability and Translation Efficiency of INHBA to Promote The Invasion and Migration of Esophageal Squamous Cancer Cells2022Research Squarepreprint
  45. MO21-4 Microbial biomarker and epidemiological factor to identify esophageal squamous cell carcinoma and precancerous lesions2022Annals of Oncologyarticle
  46. Neoadjuvant Chemoradiotherapy vs. Neoadjuvant Chemotherapy for the Treatment of Esophageal Squamous Cell Carcinoma: A Stabilized Inverse Probability of Treatment Weighting Analysis2022International Journal of Radiation Oncology*Biology*Physicsarticle
  47. Non-invasive cell-free DNA monitoring for predicting the response to neoadjuvant immunotherapy in locally advanced esophageal squamous cell carcinoma.2022Journal of Clinical Oncologyconference-abstract
  48. Survival Benefit of Surgery in Patients with Clinical T4 Esophageal Cancer Responded to Neoadjuvant Chemoradiotherapy/Radiotherapy2022International Journal of Radiation Oncology*Biology*Physicsarticle
  49. The Prognostic Value of Circulating Tumor DNA during Post-Radiotherapy Surveillance in Esophageal Squamous Cell Carcinoma2022International Journal of Radiation Oncology*Biology*Physicsarticle
  50. mRNA expression pattern study of esophageal basaloid squamous cell carcinoma.2022Journal of Clinical Oncologyconference-abstract
  51. 1373MO JUPITER-06: A randomized, double-blind, phase III study of toripalimab versus placebo in combination with first-line chemotherapy for treatment naive advanced or metastatic esophageal squamous cell carcinoma (ESCC)2021Annals of Oncologyarticle
  52. 1435TiP Adjuvant immunotherapy for resected esophageal squamous cell carcinoma with high risk of recurrence (AIRES): A multicenter, open-label, randomized, controlled phase III trial2021Annals of Oncologyarticle
  53. Abstract 1981: TGF-β induced PLEK2 promotes metastasis and chemoresistance in ESCC by up-regulation of LCN22021Cancer Researchconference-abstract
  54. Comparison of Two Major Staging Systems in Predicting Survival and Recommendation of Postoperative Radiotherapy Based on the 11th Japanese Classification for Esophageal Carcinoma After Curative Resection2021International Journal of Radiation Oncology*Biology*Physicsarticle
  55. Elevated Expression of the RNA-Binding Protein IGF2BP1 Enhances the Mrna Stability and Translation Efficiency of INHBA to Promote the Invasion and Migration of Esophageal Squamous Cancer Cells2021Research Squarepreprint
  56. Neoadjuvant camrelizumab combined with chemotherapy and apatinib for locally advanced thoracic esophageal squamous cell carcinoma (ESCC): A single-arm, open-label, phase Ib study.2021Journal of Clinical Oncologyconference-abstract
  57. Phase I study of liposomal irinotecan (LY01610) in patients with advanced esophageal squamous cell carcinoma.2021Journal of Clinical Oncologyconference-abstract

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 103 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
103
2021–2025
Trials led
8
any status, ClinicalTrials.gov
Open trials led
3
recruiting or about to
Open trials as a site
8
led by another institution
Papers led per year
2021: 181820212022: 212120222023: 222220232024: 262620242025: 12122025

17 hospitals in Beijing for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 11

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo
    Phase
    Phase 2
    Started
    2025-11
    Registry
    NCT07239245

    Age 18 years to 75 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMS; 2 listed hospitals as study sitesBeijing, Shenyang, Zhengzhou

  2. Recruiting
    Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis
    Phase
    Phase 2
    Started
    2024-05
    Registry
    NCT06389422

    Age 18 years to 90 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  3. Not yet recruiting
    SHR-1701 Plus Apatinib for Second-Line Treatment in Targeted-Immune Pretreated Advanced Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2026-08
    Registry
    NCT07749859

    Age 18 years to 75 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  4. Recruiting
    MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
    Phase
    Phase 1/Phase 2
    Started
    2026-04
    Registry
    NCT07479485

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Fuzhou, Nanjing, Tianjin, Zhengzhou

  5. Recruiting
    JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-05
    Registry
    NCT06954467

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changsha, Harbin, Hefei, Nanchang, Shanghai, Shenyang, Zhengzhou

  6. Recruiting
    Study of GV20-0251 in Participants With Solid Tumor Malignancies
    Phase
    Phase 1/Phase 2
    Started
    2025-07
    Registry
    NCT07070518

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing

  7. Recruiting
    Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2025-11
    Registry
    NCT07176650

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Bengbu, Changchun, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Zhengzhou

  8. Recruiting
    A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)
    Phase
    Phase 1/Phase 2
    Started
    2024-09
    Registry
    NCT06530251

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Jinan

  9. Recruiting
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    Phase
    Phase 3
    Started
    2023-05
    Registry
    NCT05862337

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Lanzhou, Luzhou, Nanchang, Nanchong, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Taizhou, Tianjin, Urumqi, Wenzhou, Xi'an, Zhengzhou

  10. Recruiting
    CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
    Phase
    Phase 1
    Started
    2023-10
    Registry
    NCT06560827

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou

  11. Not yet recruiting
    29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness
    Phase
    Not given
    Started
    2025-08
    Registry
    NCT07100236

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Hangzhou, Hefei, Shanghai, Wenzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImaging, AI & early detectionImmunotherapy & targeted drugs
Departments in papersRadiology / nuclear medicineSurgery (general/hepatobiliary/pancreatic)Radiation oncologyMedical oncology
Papers it led103
  1. A robust ddPCR assay for the absolute quantification of miR-192-5p in hepatocellular carcinoma liquid biopsies.2026Clinical chemistry and laboratory medicine
  2. Distinguishing between hepatocellular adenoma and well-differentiated hepatocellular carcinoma using MRI and clinical feature-based nomogram model.2026Clinical radiology
  3. Intratumoral heterogeneity of CT enhancement for component prediction and prognostic significance in combined hepatocellular carcinoma‑cholangiocarcinoma.2026European radiology
  4. Innovative rapid pathological assessment technology for hepatocellular carcinoma following comprehensive treatment guided by indocyanine green fluorescence imaging.2026Updates in surgeryFree full text
  5. Virtual MR Elastography and Multi-b-value DWI Models for Predicting Microvascular Invasion in Solitary BCLC Stage A Hepatocellular Carcinoma.2025Academic radiology
  6. Multiparametric MRI-based Machine Learning Radiomics for Predicting Treatment Response to Transarterial Chemoembolization Combined with Targeted and Immunotherapy in Unresectable Hepatocellular Carcinoma: A Multicenter Study.2025Academic radiology
  7. Accelerated Multi-b-Value DWI Using Deep Learning Reconstruction: Image Quality Improvement and Microvascular Invasion Prediction in BCLC Stage A Hepatocellular Carcinoma.2025Academic radiology
  8. Kupffer Phase Radiomics Signature in Sonazoid Contrast-Enhanced Ultrasound Predicts Immunohistochemistry Marker Expression in Hepatocellular Carcinoma.2025Cancer medicineFree full text
  9. Targeting c-MYC has a key role in hepatocellular carcinoma therapy.2025Critical reviews in oncology/hematology
  10. Combined radiation and immune checkpoint inhibitor therapy for metastatic or recurrent hepatocellular carcinoma: a real-world study of 108 patients.2025Frontiers in immunologyFree full text
  11. Nanocomposites to Overcoming Sorafenib Resistance in Hepatocellular Carcinoma Therapy.2025International journal of nanomedicineFree full text
  12. 3D dynamic magnetic microfluidic chip for efficient plasma extracellular vesicle enrichment and machine learning-based multiparametric diagnosis of hepatocellular carcinoma.2025Journal of nanobiotechnologyFree full text
  13. How different body compositions affect the prognosis of HCC undergoing immunotherapy: the paradoxical phenomenon of BMI.2025La Radiologia medica
  14. Nucleus delivery of doxorubicin by gadolinium-functionalized carbon dot drug delivery system for HCC imaging and therapy.2025Mikrochimica acta
  15. VPS45 Contributes to the Progression of Hepatocellular Carcinoma by Triggering the Wnt/β-Catenin Signaling Pathway.2025Molecular carcinogenesisFree full text
  16. Efficacy and safety of anlotinib monotherapy for advanced hepatocellular carcinoma and clinical role of α-fetoprotein.2025Scientific reportsFree full text
  17. Nomogram based on preoperative clinical and MRI features to estimate the microvascular invasion status and the prognosis of solitary intrahepatic mass-forming cholangiocarcinoma.2024Abdominal radiology (New York)
  18. Prognostic performance of MRI LI-RADS version 2018 features and clinical-pathological factors in alpha-fetoprotein-negative hepatocellular carcinoma.2024Abdominal radiology (New York)
  19. The Value of LI-RADS and Radiomic Features from MRI for Predicting Microvascular Invasion in Hepatocellular Carcinoma within 5 cm.2024Academic radiology
  20. Indocyanine Green Fluorescence-Guided Laparoscopic Anatomical Segmentectomy of Liver Segment 6: Surgical Strategy and Technical Details.2024Annals of surgical oncology
  21. A rare case of tailing effect of immunotherapy after discontinuation of antitumor therapy in a patient with hepatocellular carcinoma.2024Asian journal of surgery
  22. Hepatic arterial infusion chemotherapy plus regorafenib compared with regorafenib alone as second-line therapy for advanced hepatocellular carcinoma: a randomised controlled trial protocol.2024BMJ openFree full text
  23. Efficacy and prognostic factors of COVID-19 vaccine in patients with hepatocellular carcinoma: Analysis of data from a prospective cohort study.2024Cancer medicineFree full text
  24. Identification of molecular characteristics of hepatocellular carcinoma with microvascular invasion based on deep targeted sequencing.2024Cancer medicineFree full text
  25. Clinical benefits of intraoperative radiotherapy for the recurrence of centrally located hepatocellular carcinoma with microvascular invasion.2024Cancer reports (Hoboken, N.J.)Free full text
  26. Predicting Survival Using Whole-Liver MRI Radiomics in Patients with Hepatocellular Carcinoma After TACE Refractoriness.2024Cardiovascular and interventional radiology
  27. DKK1+ tumor cells inhibited the infiltration of CCL19+ fibroblasts and plasma cells contributing to worse immunotherapy response in hepatocellular carcinoma.2024Cell death & diseaseFree full text
  28. Survey of hepatitis B virus infection for liver cancer screening in China: A population-based, cross-sectional study.2024Chinese medical journalFree full text
  29. Reclassification of therapeutic response of unresectable hepatocellular carcinoma to anti-angiogenic therapy and immunotherapy using alpha RECIST.2024European radiology
  30. Integrating multi-omics techniques and in vitro experiments reveals that GLRX3 regulates the immune microenvironment and promotes hepatocellular carcinoma cell proliferation and invasion through iron metabolism pathways.2024Frontiers in immunologyFree full text
  31. Transarterial chemoembolization combined with lenvatinib plus tislelizumab for unresectable hepatocellular carcinoma: a multicenter cohort study.2024Frontiers in immunologyFree full text
  32. HBV integrations reshaping genomic structures promote hepatocellular carcinoma.2024GutFree full text
  33. The Role of Metabolic Reprogramming in the Tumor Immune Microenvironment: Mechanisms and Opportunities for Immunotherapy in Hepatocellular Carcinoma.2024International journal of molecular sciencesFree full text
  34. Reply to the commentary on 'Approaches of laparoscopic anatomical liver resection of segment 8 for hepatocellular carcinoma: a retrospective cohort study of short-term results at multiple centers in China'.2024International journal of surgery (London, England)Free full text
  35. Cancer-associated fibroblasts-derived exosomal ZNF250 promotes the proliferation, migration, invasion, and immune escape of hepatocellular carcinoma cells by transcriptionally activating PD-L1.2024Journal of biochemical and molecular toxicology
  36. The GRAPHS-CRAFITY score: a novel efficacy predictive tool for unresectable hepatocellular carcinoma treated with immunotherapy.2024La Radiologia medica
  37. The cumulative antitumor effects of regorafenib and radiotherapy in hepatocellular carcinoma.2024Molecular carcinogenesis
  38. Prognostic Value of Preoperative MRI-derived 3D Quantitative Tumor Arterial Burden in Patients with Hepatocellular Carcinoma Receiving Transarterial Chemoembolization.2024Radiology. Imaging cancerFree full text
  39. DGPRI, a new liver fibrosis assessment index, predicts recurrence of AFP-negative hepatocellular carcinoma after hepatic resection: a single-center retrospective study.2024Scientific reportsFree full text
  40. Surgical treatment improves overall survival of hepatocellular carcinoma with extrahepatic metastases after conversion therapy: a multicenter retrospective study.2024Scientific reportsFree full text
  41. Long-term outcome of adjuvant radiotherapy upon postoperative relapse of centrally located hepatocellular carcinoma: a real-world study.2024Scientific reportsFree full text
  42. Telomerase-related advances in hepatocellular carcinoma: A bibliometric and visual analysis.2024World journal of gastroenterologyFree full text
  43. Determination of prognostic predictors in patients with solitary hepatocellular carcinoma: histogram analysis of multiparametric MRI.2023Abdominal radiology (New York)
  44. Predictive factors of microvascular invasion in patients with intrahepatic mass-forming cholangiocarcinoma based on magnetic resonance images.2023Abdominal radiology (New York)RCT
  45. Prediction of Microvascular Invasion in Solitary AFP-Negative Hepatocellular Carcinoma ≤ 5 cm Using a Combination of Imaging Features and Quantitative Dual-Layer Spectral-Detector CT Parameters.2023Academic radiology
  46. Laparoscopic Anatomical Liver Resection of Segment VIII by Using ICG Fluorescence Positive Staining Under the Guidance of Laparoscopic Ultrasonography.2023Annals of surgical oncology
  47. Enrichment of Isaria felina Culture with Selenium Enhances its in vivo Antitumor Effects on H22 Hepatoma via Decreasing the Expression of VEGF.2023Anti-cancer agents in medicinal chemistry
  48. Using immunovascular characteristics to predict very early recurrence and prognosis of resectable intrahepatic cholangiocarcinoma.2023BMC cancerFree full text
  49. Pan-cancer analysis and experimental validation of DTL as a potential diagnosis, prognosis and immunotherapy biomarker.2023BMC cancerFree full text
  50. Noninvasive urinary protein signatures combined clinical information associated with microvascular invasion risk in HCC patients.2023BMC medicineFree full text
  51. Tumor-derived proliferative CTCs and CTC clusters predict aggressiveness and early recurrence in hepatocellular carcinoma patients.2023Cancer medicineFree full text
  52. Role of NCF2 as a potential prognostic factor and immune infiltration indicator in hepatocellular carcinoma.2023Cancer medicineFree full text
  53. Sex Differences in Genomic Features of Hepatitis B-Associated Hepatocellular Carcinoma With Distinct Antitumor Immunity.2023Cellular and molecular gastroenterology and hepatologyFree full text
  54. Microvascular invasion-negative hepatocellular carcinoma: Prognostic value of qualitative and quantitative Gd-EOB-DTPA MRI analysis.2023European journal of radiologyRCT
  55. Risk stratification of solitary hepatocellular carcinoma ≤ 5 cm without microvascular invasion: prognostic values of MR imaging features based on LI-RADS and clinical parameters.2023European radiology
  56. Immunogenicity assessment of elder hepatocellular carcinoma patients after inactivated whole-virion SARS-CoV-2 vaccination.2023Expert review of vaccines
  57. A contrast-enhanced ultrasound-based nomogram for the prediction of therapeutic efficiency of anti-PD-1 plus anti-VEGF agents in advanced hepatocellular carcinoma patients.2023Frontiers in immunologyFree full text
  58. Efficacy and safety of lenvatinib plus PD-1 inhibitor with or without transarterial chemoembolization in unresectable hepatocellular carcinoma.2023Hepatology international
  59. Hepatitis B reactivation in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis.2023Infectious diseases of povertyFree full text
  60. Approaches of laparoscopic anatomical liver resection of segment 8 for hepatocellular carcinoma: a retrospective cohort study of short-term results at multiple centers in China.2023International journal of surgery (London, England)Free full text
  61. Performance and effectiveness of hepatocellular carcinoma screening in individuals with HBsAg seropositivity in China: a multicenter prospective study.2023Nature cancer
  62. Prognostic effect of albumin-to-alkaline phosphatase ratio on patients with hepatocellular carcinoma: a systematic review and meta-analysis.2023Scientific reportsFree full text
  63. HSP90, as a functional target antigen of a mAb 11C9, promotes stemness and tumor progression in hepatocellular carcinoma.2023Stem cell research & therapyFree full text
  64. Noncoplanar Volumetric Modulated Arc Therapy for Hepatocellular Carcinoma Based on a Cage-Like Radiotherapy System: A Simulation Study.2023Technology in cancer research & treatmentFree full text
  65. Diagnostic value of whole-tumor apparent diffusion coefficient map radiomics analysis in predicting early recurrence of solitary hepatocellular carcinoma ≤ 5 cm.2022Abdominal radiology (New York)RCT
  66. Occult infection with hepatitis B virus PreS variants synergistically promotes hepatocellular carcinoma development in a high-fat diet context by generating abnormal ceramides.2022BMC medicineFree full text
  67. A Systemic Inflammation Response Index (SIRI)-Based Nomogram for Predicting the Recurrence of Early Stage Hepatocellular Carcinoma After Radiofrequency Ablation.2022Cardiovascular and interventional radiology
  68. New perspectives on ferroptosis and its role in hepatocellular carcinoma.2022Chinese medical journalFree full text
  69. Prevalence and prognostic impact of hepatopulmonary syndrome in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective cohort study.2022Chinese medical journalFree full text
  70. Integrated analysis of circulating tumour cells and circulating tumour DNA to detect minimal residual disease in hepatocellular carcinoma.2022Clinical and translational medicineFree full text
  71. Serum Concentration of CD137 and Tumor Infiltration by M1 Macrophages Predict the Response to Sintilimab plus Bevacizumab Biosimilar in Advanced Hepatocellular Carcinoma Patients.2022Clinical cancer research : an official journal of the American Association for Cancer ResearchFree full text
  72. The effectiveness of radiofrequency ablation for patients with BCLC B1 stage hepatocellular carcinoma downgraded by transarterial chemoembolization.2022Clinics and research in hepatology and gastroenterology
  73. Elevated FOXA1 Expression Indicates Poor Prognosis in Liver Cancer due to Its Effects on Cell Proliferation and Metastasis.2022Disease markersFree full text
  74. Transradial versus transfemoral access without closure device for transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized trial.2022European radiologyRCT
  75. Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma.2022Frontiers in immunologyFree full text
  76. DNA N6-Adenine methylation in HBV-related hepatocellular carcinoma.2022Gene
  77. Chinese expert recommendations on management of hepatocellular carcinoma during COVID-19 pandemic: a nationwide multicenter survey.2022HPB : the official journal of the International Hepato Pancreato Biliary AssociationFree full text
  78. Aspartate aminotransferase-to-platelet ratio index for predicting late recurrence of hepatocellular carcinoma after radiofrequency ablation.2022International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  79. Phase 2 Evaluation of Neoadjuvant Intensity-Modulated Radiotherapy in Centrally Located Hepatocellular Carcinoma: A Nonrandomized Controlled Trial.2022JAMA surgeryFree full text
  80. Delayed biopsy following completion of transarterial chemoembolization in patients with hepatocellular carcinoma: Effects on pathological outcomes and its advantages.2022Journal of cancer research and therapeutics
  81. Real-world use of IBI305, a bevacizumab biosimilar, in a tertiary caner-specialized hospital in China.2022Journal of clinical pharmacy and therapeutics
  82. The CRAFITY score: A promising prognostic predictor for patients with hepatocellular carcinoma treated with tyrosine kinase inhibitor and immunotherapy combinations.2022Journal of hepatology
  83. Emergent Transjugular Intrahepatic Portosystemic Shunt Creation for Acute Gastric Variceal Bleeding in Patients with Hepatocellular Carcinoma.2022Journal of vascular and interventional radiology : JVIR
  84. Simultaneous analysis of mutations and methylations in circulating cell-free DNA for hepatocellular carcinoma detection.2022Science translational medicine
  85. Nomograms including the controlling nutritional status score in patients with hepatocellular carcinoma undergoing transarterial chemoembolisation for prediction survival: a retrospective analysis.2022The British journal of nutrition
  86. A practical nomogram from the SEER database to predict the prognosis of hepatocellular carcinoma in patients with lymph node metastasis.2021Annals of palliative medicine
  87. Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study.2021BMC gastroenterologyFree full text
  88. Prognostic and predictive significance of the tumor microenvironment in hepatocellular carcinoma.2021Cancer biomarkers : section A of Disease markersFree full text
  89. MiR-320b/RAD21 axis affects hepatocellular carcinoma radiosensitivity to ionizing radiation treatment through DNA damage repair signaling.2021Cancer scienceFree full text
  90. Nomogram Based on Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio to Predict Recurrence in Patients with Hepatocellular Carcinoma after Radiofrequency Ablation.2021Cardiovascular and interventional radiology
  91. Retrograde transvenous obliteration for the prevention of variceal rebleeding in patients with hepatocellular carcinoma: a multicentre retrospective study.2021Clinical radiology
  92. Predictors and patterns of recurrence after radiofrequency ablation for hepatocellular carcinoma within up-to-seven criteria: A multicenter retrospective study.2021European journal of radiology
  93. Impact of perioperative allogeneic blood transfusion on the long-term prognosis of patients with different stage tumors after radical resection for hepatocellular carcinoma.2021European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  94. Late recurrence of hepatocellular carcinoma after radiofrequency ablation: a multicenter study of risk factors, patterns, and survival.2021European radiology
  95. Phase 2 Study of Adjuvant Radiotherapy Following Narrow-Margin Hepatectomy in Patients With HCC.2021Hepatology (Baltimore, Md.)Free full text
  96. Anlotinib in the treatment of advanced hepatocellular carcinoma: an open-label phase II study (ALTER-0802 study).2021Hepatology internationalFree full text
  97. Early recurrence after radiofrequency ablation for hepatocellular carcinoma: a multicenter retrospective study on definition, patterns and risk factors.2021International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  98. Establishment, validation and evaluation of predictive model for early relapse after R0 resection in hepatocellular carcinoma patients with microvascular invasion.2021Journal of translational medicineFree full text
  99. Transjugular Intrahepatic Portosystemic Shunt Creation for the Prevention of Gastric Variceal Rebleeding in Patients with Hepatocellular Carcinoma: A Multicenter Retrospective Study.2021Journal of vascular and interventional radiology : JVIR
  100. AHR mediates the aflatoxin B1 toxicity associated with hepatocellular carcinoma.2021Signal transduction and targeted therapyFree full text
  101. Chinese expert consensus on neoadjuvant and conversion therapies for hepatocellular carcinoma.2021World journal of gastroenterologyFree full text
  102. Application of artificial intelligence in preoperative imaging of hepatocellular carcinoma: Current status and future perspectives.2021World journal of gastroenterologyFree full text
  103. Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials.2021World journal of gastroenterologyFree full text
Chinese-language papers (not in the count)11
  1. [Ultrasound-guided percutaneous thermal ablation assisted by artificial ascites and soft tissue edema in the treatment of special-region hepatic tumors].2024Zhonghua zhong liu za zhi [Chinese journal of oncology]
  2. [The clinical value of heat shock protein 90α in predicting the prognosis of interventional therapy for hepatocellular carcinoma].2024Zhonghua zhong liu za zhi [Chinese journal of oncology]
  3. [The value of nomogram for predicting microvascular invasion based on clinical and Gd-EOB-DTPA-enhanced magnetic resonance imaging features].2023Zhonghua zhong liu za zhi [Chinese journal of oncology]
  4. [Lenvatinib down-regulates IGF1R/Mek/Erk signaling pathway in the treatment of regorafenib-resistant hepatocellular carcinoma].2023Zhonghua zhong liu za zhi [Chinese journal of oncology]
  5. [Urine metabolomics study of hepatocellular carcinoma].2022Zhonghua zhong liu za zhi [Chinese journal of oncology]
  6. [Pay attention to standardized treatment of hepatocellular carcinoma].2021Zhonghua wai ke za zhi [Chinese journal of surgery]
  7. [The value of autoantibodies in the diagnosis and prognosis of liver cancer].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
  8. [Analysis of risk factors and construction of predictive nomogram for early recurrence after radiofrequency ablation of hepatocellular carcinoma].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
  9. [Value of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid enhanced magnetic resonance imaging and diffusion-weighted MR imaging in predicting microvascular invasion in hepatocellular carcinoma and the prognostic significance].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
  10. [Ex-vivo experimental study of ultrasound-guided radiofrequency ablation for the treatment of hepatocellular carcinoma].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
  11. [Clinical study of peripheral vascular intervention via radial artery].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
All its trials on ClinicalTrials.gov, any status33
  1. SHR-1701 Plus Apatinib for Second-Line Treatment in Targeted-Immune Pretreated Advanced Hepatocellular CarcinomaNot yet recruitingNCT07749859Lead (inferred)Phase 2Start 2026-08
  2. Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular CarcinamoRecruitingNCT07239245Lead (inferred)Phase 2Start 2025-11
  3. Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor ThrombosisRecruitingNCT06389422Lead (inferred)Phase 2Start 2024-05
  4. Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor ThrombosisCompletedNCT06233981Lead (inferred)Phase 2Start 2024-01
  5. Application of Integrated Proteomic and Serum Metabolomic Analysis in Assessing the Efficacy and Prognosis of TACE Combined With Targeted Immunotherapy in Unresectable Hepatocellular CarcinomaStatus unknownNCT06540508Lead (inferred)Start 2023-02
  6. Safety and Efficacy Study of Sintilimab Combined With IBI305 in Patients With Advanced Hepatocellular CarcinomaCompletedNCT04072679Lead (inferred)Phase 1Start 2018-10
  7. Phase I Study of Image-Guided Radiation Concurrent With Double-Agent Chemotherapy for Hepatocellular CarcinomaStatus unknownNCT02403544Lead (inferred)Phase 1Start 2013-09
  8. Study of Postoperative 3D-CRT/IMRT in Hepatocellular CarcinomaCompletedNCT01456156Lead (inferred)N/AStart 2008-01
  9. MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)RecruitingNCT07479485Study sitePhase 1/Phase 2Start 2026-04
  10. Study of GV20-0251 in Participants With Solid Tumor MalignanciesRecruitingNCT07070518Study sitePhase 1/Phase 2Start 2025-07
  11. 29-Gene Liver Cancer Subtype and Immunotherapy EffectivenessNot yet recruitingNCT07100236Study siteStart 2025-08
  12. JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular CarcinomaRecruitingNCT06954467Study sitePhase 2Start 2025-05
  13. Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular CarcinomaRecruitingNCT07176650Study sitePhase 1Start 2025-11
  14. A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)RecruitingNCT06530251Study sitePhase 1/Phase 2Start 2024-09
  15. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.RecruitingNCT05862337Study sitePhase 3Start 2023-05
  16. CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical ResectionRecruitingNCT06560827Study sitePhase 1Start 2023-10
  17. NWRD06 DNA Plasmid for HCC After Radical ResectionStatus unknownNCT06088459Study sitePhase 1Start 2023-11
  18. the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular CarcinomaStatus unknownNCT05408221Study sitePhase 2/Phase 3Start 2022-11
  19. NewishT Cell Therapy for HCC With High Risk of Recurrence After Radical ResectionStatus unknownNCT05352646Study sitePhase 1Start 2022-07
  20. Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)Status unknownNCT04741165Study sitePhase 2Start 2021-01
  21. A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCCCompletedNCT04948697Study sitePhase 2Start 2021-08
  22. A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/BevActive, not recruitingNCT04649489Study sitePhase 3Start 2021-04
  23. YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)CompletedNCT04000737Study sitePhase 2Start 2020-01
  24. To Evaluate the Safety and Efficacy of Microwave Ablation Therapy in Patients With Primary Liver CancerTerminatedNCT04520906Study siteN/AStart 2020-12
  25. A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCCCompletedNCT03764293Study sitePhase 3Start 2019-06
  26. A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular CarcinomaStatus unknownNCT03825705Study sitePhase 1/Phase 2Start 2019-04
  27. Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)CompletedNCT03867084Study sitePhase 3Start 2019-05
  28. Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)CompletedNCT03713593Study sitePhase 3Start 2018-12
  29. A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)CompletedNCT03412773Study sitePhase 3Start 2017-12
  30. The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma SubjectsStatus unknownNCT03236636Study sitePhase 3Start 2017-09
  31. STOPPER CHINA:With Tandem Microspheres in the Treatment of Localized Hepatocellular CarcinomaCompletedNCT03113955Study siteN/AStart 2017-10
  32. A Study to Evaluate SHR-1210 in Subjects With Advanced HCCCompletedNCT02989922Study sitePhase 2Start 2016-11
  33. HepaSphere Chemoembolization in Advanced HCC Patients: Safety & Efficacy Registry in ChinaStatus unknownNCT02743065Study siteStart 2016-09

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 131 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 1.3%.

Papers led
131
2021–2025
Trials led
16
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
6
led by another institution
Papers led per year
2021: 202020212022: 262620222023: 171720232024: 242420242025: 39392025

15 hospitals in Beijing for stomach cancer211 hospitals in China for stomach cancer

Open trials with this hospital 8

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma
    Phase
    Not given
    Started
    2024-04
    Registry
    NCT06417892

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  2. Recruiting
    Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer
    Phase
    Phase 2
    Started
    2024-11
    Registry
    NCT06711471

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  3. Recruiting
    Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric Cancer
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07689851

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shenzhen, Taiyuan

  4. Recruiting
    Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
    Phase
    Not given
    Started
    2025-02
    Registry
    NCT06846996

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 32 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Haikou, Hangzhou, Nanjing, Shanghai, Shantou, Shenyang, Taiyuan, Taizhou, Tianjin, Xuzhou, Zhengzhou

  5. Recruiting
    SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
    Phase
    Phase 1
    Started
    2025-02
    Registry
    NCT06873659

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Jinan, Lanzhou, Nanjing, Shanghai, Xi'an

  6. Recruiting
    A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
    Phase
    Phase 3
    Started
    2024-11
    Registry
    NCT06532006

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 36 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Lanzhou, Luoyang, Nanchang, Nanjing, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Xiamen, Xining, Xuzhou, Yinchuan, Zhengzhou

  7. Recruiting
    A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2022-01
    Registry
    NCT05150691

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou

  8. Not yet recruiting
    A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway
    Phase
    Phase 1
    Started
    2024-11
    Registry
    NCT06614751

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesChemotherapy & combined treatmentPeritoneal spread & advanced diseaseSurgery
Departments in papersSurgery (general/hepatobiliary/pancreatic)Medical oncologyGastroenterology / hepatologyPathology / laboratory medicine
Papers it led131
  1. Lymph Node Metastasis Frequency and Development of Predictive Model in T1b Gastric Cancer: A Single-Center Study.2026Annals of surgical oncology
  2. Correlation of G protein-coupled receptor and tumor microenvironment with gastric cancer outcomes and therapies.2026Chinese medical journalFree full text
  3. Neoadjuvant chemotherapy with docetaxel, oxaliplatin, and S-1 versus oxaliplatin and S-1 for locally advanced gastric adenocarcinoma: A multicenter, real-world cohort study.2026International journal of cancer
  4. Efficacy and safety of fruquintinib combined with albumin-bound paclitaxel as second-line therapy for advanced gastric cancer following failure of PD-1 inhibitor-containing treatment (TACTIC GC-01): A phase II single-arm study.2026International journal of cancerFree full text
  5. Peritoneal lavage fluid minimal residual cancer cells detection for early prediction of peritoneal metastasis in gastric cancer: A multi-cohort validation study.2026International journal of cancer
  6. Downstaging Effect Rather than the Full Intended Cycles of Perioperative Chemotherapy Determines the Value of Adjuvant Chemotherapy in Gastric Cancer.2025Annals of surgical oncology
  7. Survival and Metastatic Lymph Node Patterns in Gastric Carcinoma with Exocrine and Neuroendocrine Components.2025Annals of surgical oncology
  8. Association between adjuvant radiotherapy in adults with gastric cancer and risk of second primary malignancy: a retrospective cohort study using the Surveillance, Epidemiology and End Results database.2025BMJ openFree full text
  9. Predictive factors for neoadjuvant combined immunotherapy in gastric adenocarcinoma: Focusing on the primitive enterocyte phenotype and PVR.2025British journal of cancerFree full text
  10. Clinical pathological and molecular features of 100 patients with gastric-type cervical adenocarcinoma.2025Diagnostic pathologyFree full text
  11. Assessment of the participation rate and effectiveness of upper gastrointestinal cancer screening in China: a multicenter population-based screening study.2025Endoscopy
  12. Integrated Analysis of Serum and Tissue microRNA Transcriptome for Biomarker Discovery in Gastric Cancer.2025Environmental toxicology
  13. Mechanism of methyltransferase METTL14 mediating m6A modification and regulating SIRT5 expression to promote ferroptosis and repress gastric cancer progression.2025European journal of medical researchFree full text
  14. Management of liver metastases from non-functional gastroenteropancreatic neuroendocrine tumors: a systematic review.2025Frontiers in endocrinologyFree full text
  15. Inhibition of human gastric cancer growth by cytokine-induced killer cells plus chemotherapy with or without cadonilimab in a mouse xenograft tumor model.2025Frontiers in immunologyFree full text
  16. Interpretable deep learning for gastric cancer detection: a fusion of AI architectures and explainability analysis.2025Frontiers in immunologyFree full text
  17. NALCN expression is down-regulated and associated with immune infiltration in gastric cancer.2025Frontiers in immunologyFree full text
  18. Genomic landscape and potential therapeutic targets in alpha-fetoprotein-producing gastric cancer.2025Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer AssociationFree full text
  19. Effect of an Endoscopy Screening on Upper Gastrointestinal Cancer Mortality: A Community-Based Multicenter Cluster Randomized Clinical Trial.2025GastroenterologyRCT
  20. Clinicopathological characteristics and immune infiltration analysis of esophagogastric junction adenocarcinoma with alterations in SWI/SNF complex.2025Human pathology
  21. Bio-engineered cancer cell membrane and chitosan-coated core-shell SiO₂@au nanoparticles co-loaded with sophoridine for targeted chemo-photodynamic therapy of gastric adenocarcinoma cells: In vitro and in vivo analysis.2025International journal of biological macromolecules
  22. Balanced diet quality and risk of upper gastrointestinal cancers: Insights from a prospective cohort study in China.2025International journal of cancer
  23. Halofuginone induces ERK phosphorylation and synergizes with trametinib in gastric cancer cells.2025International journal of immunopathology and pharmacologyFree full text
  24. Long-Term Prognostic Analysis of Chemoradiation Therapy Versus Chemotherapy after D2 Resection for High-Risk Gastric Cancer: Results From a Prospective Randomized Control Study.2025International journal of radiation oncology, biology, physicsRCT
  25. A Comprehensive Analysis of the Association Between the EORTC QLQ-C30 Questionnaire and Cachexia in Patients With Gastric Cancer.2025Journal of cachexia, sarcopenia and muscleFree full text
  26. Is Proximal Gastrectomy Oncologically Justifiable for Advanced Siewert II/III Adenocarcinoma of the Esophagogastric Junction?2025Journal of gastric cancerFree full text
  27. Temporospatial variation in environmental risk factors and related gastric cancer incidence: a registry-based study in an area with the largest gastric cancer burden in China.2025Journal of global healthFree full text
  28. HSP90 co-regulates the formation and nuclear distribution of the glycolytic output complex to promote resistance and poor prognosis in gastric cancer patients.2025Journal of translational medicineFree full text
  29. Development and validation of a machine learning-based prognostic model for gastric cancer: a multicenter retrospective study.2025Langenbeck's archives of surgeryFree full text
  30. Patient-derived tumor xenograft animal model of gastric cancer in precision chemotherapy.2025Naunyn-Schmiedeberg's archives of pharmacology
  31. High glycolysis phenotype influences malignant progression and poor prognosis of gastric cancer through the PI3K/AKT pathway.2025Neoplasma
  32. Evaluating the predictive significance of D-dimer in conjunction with CA724 for the postoperative outcomes in gastric cancer: A retrospective cohort analysis.2025PloS oneFree full text
  33. Can patients with mild non-neoplastic lesions diagnosed at baseline screening be safely exempt from surveillance: evidence from multicenter community-based cohorts.2025Science China. Life sciences
  34. MiR-106b-5p promotes gastric cancer progression by directly targeting the tumor suppressor RBL2.2025Scientific reportsFree full text
  35. Causal association between EBV and gastritis, gastric cancer, and gastric ulcer: a two-sample Mendelian randomization study.2025Scientific reportsFree full text
  36. The prognostic and immunomodulatory role of the MMR system in patients with stomach adenocarcinoma.2025Scientific reportsFree full text
  37. Alpha-enolase influences ATP pool of cytoplasm and lactate homeostasis by regulating glycolysis in gastric cancer.2025Signal transduction and targeted therapyFree full text
  38. The global and regional burden of early-onset gastric cancer (15-49 years, 1990-2021): incidence and mortality with projections to 2030.2025The oncologistFree full text
  39. Tumor stroma ratio, tumor stroma maturity, tumor-infiltrating immune cells in relation to prognosis, and neoadjuvant therapy response in esophagogastric junction adenocarcinoma.2025Virchows Archiv : an international journal of pathology
  40. Circular RNA contributes to gastric cancer by targeting Wnt family member 2B as a competing endogenous RNA.2025World journal of gastroenterologyFree full text
  41. The relationship between examined lymph nodes and oncological outcome of proximal gastrectomy for Siewert II/III adenocarcinoma of the esophagogastric junction.2025World journal of surgical oncologyFree full text
  42. Exploring the prognosis of rictor(+) in high-risk population: lasso regression for enhancing overall survival in primary gastric adenocarcinoma.2025World journal of surgical oncologyFree full text
  43. Comparative outcomes of laparoscopic and open gastrectomy for T4b gastric cancer with transverse colon or mesentery invasion: a dual-center retrospective analysis.2025World journal of surgical oncologyFree full text
  44. The transhiatal tunnel valvuloplasty technique following laparoscopic proximal gastrectomy: the single-center experience in a retrospective cohort.2025World journal of surgical oncologyFree full text
  45. Hsp90 Promotes Gastric Cancer Cell Metastasis and Stemness by Regulating the Regional Distribution of Glycolysis-Related Metabolic Enzymes in the Cytoplasm.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  46. ASO Author Reflections: Effect of the Number of Examined Lymph Nodes on Survival in Gastric Signet-Ring Cell Cancer.2024Annals of surgical oncology
  47. Impact of Removal of Lymph Nodes on Survival in Stage I-III Gastric Signet-Ring Cell Cancer: The More, the Better?2024Annals of surgical oncology
  48. Intraperitoneal Irrigation Chemotherapy with Lobaplatin in Locally Advanced Gastric Cancer: A Special Type of Abdominal Chemotherapy.2024Asian Pacific journal of cancer prevention : APJCPFree full text
  49. Sex disparity, prediagnosis lifestyle factors, and long-term survival of gastric cancer: a multi-center cohort study from China.2024BMC cancerFree full text
  50. Global, regional, and national burden of early-onset gastric cancer.2024Cancer biology & medicineFree full text
  51. Gastric Mucosal Status and Risk of Gastric Cancer in High-Risk Individuals: A Population-Based, Multicenter Prospective Study in China.2024Cancer medicineFree full text
  52. Endoscopic hand suturing with clips for a large defect after endoscopic full-thickness resection of gastric gastrointestinal stromal tumor.2024EndoscopyFree full text
  53. Impact of interaction between interleukin-6 gene polymorphism and Helicobacter pylori infection on susceptibility to gastric cancer.2024European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  54. Analysis of the treatment efficacy and prognostic factors of PD-1/PD-L1 inhibitors for advanced gastric or gastroesophageal junction cancer: a multicenter, retrospective clinical study.2024Frontiers in immunologyFree full text
  55. A novel web-based dynamic prognostic nomogram for gastric signet ring cell carcinoma: a multicenter population-based study.2024Frontiers in immunologyFree full text
  56. Gastric tubular adenocarcinoma with diffuse neutrophils infiltrating: characteristics and probable treatment strategy.2024Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  57. Perioperative chemotherapy with docetaxel plus oxaliplatin and S-1 (DOS) versus oxaliplatin plus S-1 (SOX) for the treatment of locally advanced gastric or gastro-esophageal junction adenocarcinoma (MATCH): an open-label, randomized, phase 2024Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer AssociationRCTFree full text
  58. GLI1, CDK4, and MDM2 Co-Amplification Gastric Plexiform Fibromyxoma: A Case Report and Literature Review.2024Genes, chromosomes & cancer
  59. Impact of primary tumor resection and metastasectomy among gastroentero-pancreatic neuroendocrine tumors with liver metastases only on survival.2024HPB : the official journal of the International Hepato Pancreato Biliary Association
  60. The current infection with Helicobacter pylori and association with upper gastrointestinal lesions and risk of upper gastrointestinal cancer: Insights from multicenter population-based cohort study.2024International journal of cancer
  61. Blood transfusion might not be recommended for gastric cancer patients with pretransfusion minimum hemoglobin values higher than 90 g/l: a real-world study covering 20 years of 13 470 patients.2024International journal of surgery (London, England)Free full text
  62. Evaluation of pathologic response and surgical safety of total neoadjuvant therapy for patients with clinical stage III gastric cancer in a real-world setting.2024Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  63. Personalized starting age of gastric cancer screening based on individuals' risk profiles: a population-based, prospective study.2024Journal of the National Cancer Institute
  64. Bugs as drugs: Extended clinical applications and potential translational trends of Akkermansia muciniphila in oncology and comprehensive clinical investigation panorama of therapeutic microbiome modulators in gastric cancer treatment.2024Pharmacological research
  65. Securinine inhibits carcinogenesis in gastric cancer by targeting AURKA-β-catenin/Akt/STAT3 and the cell cycle pathway.2024Phytomedicine : international journal of phytotherapy and phytopharmacology
  66. Novel DNA methylation markers for early detection of gastric cardia adenocarcinoma and esophageal squamous cell carcinoma.2024Science China. Life sciences
  67. A prospective phase II clinical trial of total neoadjuvant therapy for locally advanced gastric cancer and gastroesophageal junction adenocarcinoma.2024Scientific reportsFree full text
  68. The change of symptom clusters in gastric cancer patients during the perioperative period: a longitudinal study.2024Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  69. The minimum number of examined lymph nodes was 24 for optimal survival of pathological T2-4 gastric cancer: a multi-center, hospital-based study covering 20 years of data.2023BMC cancerFree full text
  70. Association between type of drinking water and upper gastrointestinal cancer incidence in the Linxian General Population.2023BMC cancerFree full text
  71. Short-term and long-term effect of nutrition intervention in the Linxian Dysplasia Nutrition Intervention Trial and the reason for disappearance of the intervention effect: A cohort study.2023CancerRCT
  72. Perioperative treatment and biomarker analysis of LP002, an anti-PD-L1 antibody, plus chemotherapy in resectable gastric and gastroesophageal junction cancer.2023Cancer medicineFree full text
  73. Adjuvant chemotherapy may be unnecessary for ypT0-2N0 gastric cancer patients after neoadjuvant chemotherapy and curative gastrectomy.2023Chinese medical journalFree full text
  74. Real-World Practice of Gastric Cancer Prevention and Screening Calls for Practical Prediction Models.2023Clinical and translational gastroenterologyFree full text
  75. A systematic review and meta-analysis on the relative and attributable risk of Helicobacter pylori infection and cardia and non-cardia gastric cancer.2023Expert review of molecular diagnostics
  76. Autologous CIK cells combined with chemotherapy as the first-line treatment for locally advanced or metastatic gastric cancer is safe and feasible.2023Frontiers in immunologyRCTFree full text
  77. Time to surgery does not affect oncologic outcomes in locally advanced gastric cancer after neoadjuvant chemotherapy: a meta-analysis.2023Future oncology (London, England)
  78. Impact of surgical approach on short- and long-term outcomes in gastroenteropancreatic neuroendocrine carcinomas.2023HPB : the official journal of the International Hepato Pancreato Biliary Association
  79. LncRNA MIR155HG Overexpression Promotes Proliferation, Migration, and Chemoresistance in Gastric Cancer Cells.2023International journal of medical sciencesFree full text
  80. Laparoscopic endoscopic cooperative surgery for the duodenal neuroendocrine tumor: a single-center case series (How I Do It).2023International journal of surgery (London, England)Free full text
  81. A gastric neuroendocrine carcinoma with good prognosis after chemotherapy combined with immunotherapy: A case report (CARE-compliant).2023MedicineFree full text
  82. Total Lymph Node Yield Is Associated with Prolonged Survival after Neoadjuvant Chemotherapy in ypN0 Gastric Cancer Patients.2023Oncology research and treatment
  83. Perioperative Chemotherapy Could Not Improve the Prognosis of Gastric Cancer Patients With Mismatch Repair Deficiency: A Multicenter, Real-World Study.2023The oncologistFree full text
  84. Survival benefit of younger gastric cancer patients in China and the United States: A comparative study.2023World journal of gastroenterologyFree full text
  85. Identification of critical prognosis signature associated with lymph node metastasis of stomach adenocarcinomas.2023World journal of surgical oncologyFree full text
  86. Biweekly oxaliplatin plus S1 for Chinese elderly patients with advanced gastric or gastroesophageal junction cancer as the first-line therapy: a single-arm, phase 2 study.2022BMC cancerFree full text
  87. Preoperative versus postoperative chemo-radiotherapy for locally advanced gastric cancer: a multicenter propensity score-matched analysis.2022BMC cancerFree full text
  88. A 9‑gene expression signature to predict stage development in resectable stomach adenocarcinoma.2022BMC gastroenterologyFree full text
  89. Total neoadjuvant therapy for locally advanced gastric cancer and esophagogastric junction adenocarcinoma: study protocol for a prospective, multicenter, single-arm, phase II clinical trial.2022BMC gastroenterologyFree full text
  90. Sporadic foveolar-type adenoma in gastric body/antrum junction with gastritis cystica profunda.2022BMC gastroenterologyFree full text
  91. Hyperthermic intraperitoneal chemotherapy for patients with gastric cancer based on laboratory tests is safe: a single Chinese center analysis.2022BMC surgeryFree full text
  92. Can Gastric Cancer Patients with High Mandard Score Benefit from Neoadjuvant Chemotherapy?2022Canadian journal of gastroenterology & hepatologyFree full text
  93. Clinicopathological characteristics, survival outcomes, and genetic alterations of younger patients with gastric cancer: Results from the China National Cancer Center and cBioPortal datasets.2022Cancer medicineFree full text
  94. Gastric and esophageal cancer in China 2000 to 2030: Recent trends and short-term predictions of the future burden.2022Cancer medicineFree full text
  95. Prediction Models for Gastric Cancer Risk in the General Population: A Systematic Review.2022Cancer prevention research (Philadelphia, Pa.)
  96. Associations between cancer family history and esophageal cancer and precancerous lesions in high-risk areas of China.2022Chinese medical journalFree full text
  97. Gastric inverted hyperplastic polyp, an exceptional case diagnosed after endoscopic submucosal dissection.2022Clinics and research in hepatology and gastroenterology
  98. Better Prognosis of Gastric Neuroendocrine Carcinoma Than Gastric Adenocarcinoma among Whites in the United States: A Propensity Score Matching Analysis Based on SEER.2022Current oncology (Toronto, Ont.)Free full text
  99. miR-33a-5p Targets RAP2A to Mediate the Sensitivity of Gastric Cancer Cells to 5-FU.2022Disease markersFree full text
  100. Profiling the peripheral blood T cell receptor repertoires of gastric cancer patients.2022Frontiers in immunologyFree full text
  101. Deep learning predicts resistance to neoadjuvant chemotherapy for locally advanced gastric cancer: a multicenter study.2022Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  102. Comment on: "Internal hernia after gastrectomy for gastric cancer in minimally invasive surgery era," Gastric Cancer, 2019 Feb 13, by Kang et al.2022Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  103. Combined risk factors and risk of upper gastrointestinal cancer mortality in the Linxian general population.2022International journal of cancer
  104. Global and national trends in the age-specific sex ratio of esophageal cancer and gastric cancer by subtype.2022International journal of cancerFree full text
  105. Reconstruction of the gastric cancer microenvironment after neoadjuvant chemotherapy by longitudinal single-cell sequencing.2022Journal of translational medicineFree full text
  106. Association of Sarcopenia and Expression of Interleukin-16 in Gastric Cancer Survival.2022NutrientsFree full text
  107. Interaction Between Vascular Endothelial Growth Factor Gene Polymorphism and Smoking on Gastric Cancer Risk in Chinese Han Population.2022Pathology oncology research : PORFree full text
  108. Assessment and validation of the internal gross tumour volume of gastroesophageal junction cancer during simultaneous integrated boost radiotherapy.2022Radiation oncology (London, England)Free full text
  109. Single-cell landscape reveals active cell subtypes and their interaction in the tumor microenvironment of gastric cancer.2022TheranosticsFree full text
  110. No long-term survival benefit with sustained-release 5-fluorouracil implants in patients with stages II and III gastric cancer.2022World journal of gastroenterologyFree full text
  111. A new scoring system to evaluate adjuvant chemotherapy for patients with T2N0M0 gastric cancer after D2 gastrectomy.2022World journal of gastroenterologyFree full text
  112. Clinical practice and outcome of radiotherapy for advanced esophageal squamous cell carcinoma between 2002 and 2018 in China: the multi-center 3JECROG Survey.2021Acta oncologica (Stockholm, Sweden)
  113. Comment on "Resection of the Primary Gastrointestinal Neuroendocrine Tumor Improves Survival With or Without Liver Treatment".2021Annals of surgery
  114. Both the serum AFP test and AFP/GPC3/SALL4 immunohistochemistry are beneficial for predicting the prognosis of gastric adenocarcinoma.2021BMC gastroenterologyFree full text
  115. Regional and racial disparity in proximal gastric cancer survival outcomes 1996-2016: Results from SEER and China National Cancer Center database.2021Cancer medicineFree full text
  116. Serum Levels of Androgens, Estrogens, and Sex Hormone Binding Globulin and Risk of Primary Gastric Cancer in Chinese Men: A Nested Case-Control Study.2021Cancer prevention research (Philadelphia, Pa.)Free full text
  117. Exceeding 30 ELNs is strongly recommended for pT3-4N0 patients with gastric cancer: A multicenter study of survival, recurrence, and prediction model.2021Cancer scienceFree full text
  118. Alcohol consumption and risk of stomach cancer: A meta-analysis.2021Chemico-biological interactions
  119. Risk factors for gastric cancer: a large-scale, population-based case-control study.2021Chinese medical journalFree full text
  120. Adjuvant chemotherapy indications for stage I gastric cancer patients with negative lymph node.2021Clinics and research in hepatology and gastroenterology
  121. Clinical Outcomes of Proximal Gastrectomy versus Total Gastrectomy for Proximal Gastric Cancer: A Systematic Review and Meta-Analysis.2021Digestive surgery
  122. Effectiveness of one-time endoscopic screening programme in prevention of upper gastrointestinal cancer in China: a multicentre population-based cohort study.2021GutFree full text
  123. Surveillance of premalignant gastric cardia lesions: A population-based prospective cohort study in China.2021International journal of cancer
  124. Indications for adjuvant chemotherapy in patients with pT1N1M0 gastric cancer: a single-center experience.2021Journal of cancer research and clinical oncologyFree full text
  125. Personalized analysis of minimal residual cancer cells in peritoneal lavage fluid predicts peritoneal dissemination of gastric cancer.2021Journal of hematology & oncologyFree full text
  126. Is Additional Surgery Necessary After Non-Curative Endoscopic Submucosal Dissection for Early Colorectal Cancer?2021Journal of investigative surgery : the official journal of the Academy of Surgical Research
  127. The efficacy of the application of the curative criteria of the 5rd edition Japanese gastric cancer treatment guidelines for early adenocarcinoma of the esophagogastric junction treated by endoscopic submucosal dissection.2021Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology AssociationFree full text
  128. Population Attributable Risks of Subtypes of Esophageal and Gastric Cancers in the United States.2021The American journal of gastroenterologyFree full text
  129. Gastric cancer with repeated metastasis in the colonic lumen: a case report and multi-surgical experience.2021The Journal of international medical researchFree full text
  130. Disparities in stage at diagnosis for five common cancers in China: a multicentre, hospital-based, observational study.2021The Lancet. Public health
  131. Feasibility of totally laparoscopic gastrectomy without prophylactic drains in gastric cancer patients.2021World journal of gastroenterologyFree full text
Chinese-language papers (not in the count)20
  1. [Characteristics of gastric hepatoid adenocarcinoma: a clinicopathological and molecular analysis].2025Zhonghua bing li xue za zhi = Chinese journal of pathology
  2. [A real-world study of 15,644 patients undergoing D2 radical gastrectomy over 11 years at Shanxi provincial cancer hospital].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  3. [Overview of screening and early detection of primary malignant tumors in general population in China].2025Zhonghua zhong liu za zhi [Chinese journal of oncology]
  4. [The efficacy and safety of laparoscopic radical gastrectomy after neoadjuvant chemotherapy combined with immunotherapy and targeted therapy].2024Zhonghua yi xue za zhi
  5. [Analysis of prognostic risk factors for patients with locally advanced gastric cancer in the stage ypT0~2N0M0 after neoadjuvant chemotherapy].2024Zhonghua zhong liu za zhi [Chinese journal of oncology]
  6. [Clinicopathological analysis of gastric adenocarcinoma with elevated serum alpha-fetoprotein and enteroblastic differentiation].2024Zhonghua zhong liu za zhi [Chinese journal of oncology]
  7. [Therapeutic efficacy analysis of endoscopic combined with serological diagnosis strategy and endoscopic in G1 and G2 gastric neuroendocrine neoplasms].2024Zhonghua zhong liu za zhi [Chinese journal of oncology]
  8. [Preliminary report on the use of total lumpectomyconical remnant gastric - esophagus side overlap anastomosis in radical resection of Siewert type II proximal gastric cancer].2023Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  9. [Diagnostic methods for peritoneal molecular residual disease in gastric cancer].2023Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  10. [Factors associated with readmission within three months of surgery for gastric cancer and their long-term effects on patients' nutritional status and quality of life].2023Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  11. [Attach importance to the research of membrane surgery in an era of precision medicine].2022Zhonghua yi xue za zhi
  12. [Regional disparities in trends of global gastric cancer incidence and mortality from 1990 to 2019].2022Zhonghua zhong liu za zhi [Chinese journal of oncology]
  13. [China guideline for the screening, early detection and early treatment of gastric cancer (2022, Beijing)].2022Zhonghua zhong liu za zhi [Chinese journal of oncology]
  14. [Quality assessment of guidelines on upper gastrointestinal cancer screening].2021Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi
  15. [Comparison of long-term outcomes between endoscopic submucosal dissection and surgical resection for early gastric cancer with undifferentiated histology].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  16. [Postoperative complications and their influence on the prognosis factors in gastric cancer patients receiving neoadjuvant treatment].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  17. [Advances in molecular classification and precision immunotherapy for gastric cancer].2021Zhonghua yi xue za zhi
  18. [Long-term efficacy and safety of simultaneous integrated boost radiotherapy in non-operative esophageal squamous cell carcinoma: a multicenter retrospective data analysis (3JECROG R-05)].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
  19. [Analysis of risk factors for delayed bleeding after endoscopic submucosal dissection of gastric epithelial neoplasm].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
  20. [Consensus and controversy on accurate diagnosis and treatment of resectable gastric cancer].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
All its trials on ClinicalTrials.gov, any status41
  1. Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric CancerRecruitingNCT06711471Lead (inferred)Phase 2Start 2024-11
  2. Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ AdenocarcinomaRecruitingNCT06417892Lead (inferred)Start 2024-04
  3. Transhiatal Tunnel Valvuloplasty for Reconstruction Following the Laparoscopic Proximal GastrectomyStatus unknownNCT06354036Lead (inferred)N/AStart 2023-03
  4. Gastric Cancer Organoids in the Screening of Neoadjuvant DrugsStatus unknownNCT06196554Lead (inferred)Start 2023-05
  5. Neo-Sequence 1: Neoadjuvant Chemotherapy With or Without Antiangiogenesis and Sequential Immunotherapy for HER2-negative MMR-proficient Locally Advanced Gastric or Gastroesophageal AdenocarcinomaCompletedNCT05540145Lead (inferred)Start 2022-05
  6. Intraperitoneal Chemotherapy Guided by the Detection of DNA in Peritoneal Lavage Fluid in Patients With Gastric CancerStatus unknownNCT05497739Lead (inferred)Phase 2Start 2022-06
  7. A Phase II Study of Total Neoadjuvant Therapy for Locally Advanced Gastric CancerStatus unknownNCT04062058Lead (inferred)Phase 2Start 2019-11
  8. Perioperative Electroacupuncture for Gastric Cancer Patients After GastrectomyStatus unknownNCT03291574Lead (inferred)N/AStart 2017-07
  9. Study of Hypo-fractionated Neoadjuvant Radiotherapy for Locally Advanced Gastric CancerStatus unknownNCT03427684Lead (inferred)Phase 1/Phase 2Start 2016-05
  10. Efficacy and Safety of S-1 Plus Oxaliplatin in First-line Treatment of Ederly Patients With Advanced Gastric CancerStatus unknownNCT04694404Lead (inferred)Phase 2Start 2016-05
  11. A Randomized Phase III Study of Adjuvant Chemotherapy With or Without Chemo-radiotherapy in Patients With Local Advanced Gastric Cancer After D2 Resection.Status unknownNCT02648841Lead (inferred)Phase 3Start 2015-07
  12. A Randomized Phase II Trial of Neoadjuvant Chemotherapy Compared With Chemoradiotherapy in Gastric AdenocarcinomaCompletedNCT02301481Lead (inferred)Phase 2Start 2014-01
  13. A Phase II Study of Postoperative S-1-Based Chemoradiotherapy in Gastric CancerStatus unknownNCT02296658Lead (inferred)Phase 2Start 2014-01
  14. Combination of Nimotuzumab,Capecitabine and Radiotherapy for Inoperable or Recurrent Gastric CancerStatus unknownNCT01180166Lead (inferred)Phase 2Start 2010-05
  15. A Phase I Study of S-1 in Combination With Radiotherapy in Locally Advanced or Recurrent Gastric CancerCompletedNCT01291407Lead (inferred)Phase 1Start 2010-11
  16. Cisplatin and S-1 With or Without Nimotuzumab in Untreated Advanced Gastric AdenocarcinomaCompletedNCT02370849Lead (inferred)Phase 2Start 2009-10
  17. Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric CancerRecruitingNCT07689851Study sitePhase 2Start 2026-07
  18. SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid TumorsRecruitingNCT06873659Study sitePhase 1Start 2025-02
  19. Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in ChinaRecruitingNCT06846996Study siteStart 2025-02
  20. A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR PathwayNot yet recruitingNCT06614751Study sitePhase 1Start 2024-11
  21. A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric CancerRecruitingNCT06532006Study sitePhase 3Start 2024-11
  22. A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsRecruitingNCT05150691Study sitePhase 1/Phase 2Start 2022-01
  23. Exosome-based Liquid Biopsies for Upper Gastrointestinal Cancers DiagnosisStatus unknownNCT06278064Study siteStart 2024-02
  24. A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or AmplificationTerminatedNCT06585488Study sitePhase 1Start 2024-12
  25. A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage TumorsActive, not recruitingNCT06257264Study sitePhase 1Start 2024-03
  26. Plasma Metabolic Biomarkers for Multi-Cancer DiagnosisStatus unknownNCT06363123Study siteStart 2024-03
  27. Plasma Metabolic Biomarkers for Gastric Cancer DiagnosisCompletedNCT06109805Study siteStart 2023-10
  28. A Study of MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer.Status unknownNCT05141747Study sitePhase 2Start 2022-01
  29. Clinical Trial of Yiqi Wenyang Jiedu Prescription in the Prevention and Treatment of Postoperative Metastasis and Recurrence of Gastric CancerStatus unknownNCT05229809Study sitePhase 4Start 2022-03
  30. Study of ESG401 in Adults With Solid TumorsCompletedNCT04892342Study sitePhase 1/Phase 2Start 2021-09
  31. Multi-Omics Noninvasive Inspection of TumOr Risk for Gastric CancerStatus unknownNCT04947995Study siteStart 2021-06
  32. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersActive, not recruitingNCT05152147Study sitePhase 3Start 2021-12
  33. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric CancerStatus unknownNCT04486651Study sitePhase 3Start 2020-09
  34. Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric CancerActive, not recruitingNCT04208347Study sitePhase 2/Phase 3Start 2019-12
  35. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)CompletedNCT03675737Study sitePhase 3Start 2018-11
  36. Second-line CM082 Combined With Paclitaxel For Patients With Advanced Gastric CancerStatus unknownNCT03286244Study sitePhase 1Start 2018-03
  37. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China ExtensionWithdrawnNCT04859582Study sitePhase 3Start 2018-11
  38. Study Evaluating Pyrotinib/Pyrotinib in Combination With Docetaxel in Patients With HER2+ Advanced Gastric CancerStatus unknownNCT02378389Study sitePhase 1Start 2014-09
  39. A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction CancerCompletedNCT02178956Study sitePhase 3Start 2014-10
  40. A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric CancerCompletedNCT01774786Study sitePhase 3Start 2013-06
  41. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric CancerCompletedNCT01839500Study siteStart 2013-04

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 8 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
8
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 5520242025: 112025

37 hospitals in Beijing for osteosarcoma570 hospitals in China for osteosarcoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Phase I Study of XS-02 Capsules in Patients With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2024-08
    Registry
    NCT06531486

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersMedical oncology

Over half of these papers are lab or animal studies.

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 1 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

19 hospitals in Beijing for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led1
  1. Endoscopic hand suturing with clips for a large defect after endoscopic full-thickness resection of gastric gastrointestinal stromal tumor.2024EndoscopyFree full text
Earlier papers (2016–2020)9
  1. Resection Combined with TKI Therapy for Resectable Liver Metastases of Gastrointestinal Stromal Tumours: Results from Three National Centres in China.2020Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  2. Radiofrequency ablation versus resection for resectable liver metastases of gastrointestinal stromal tumours: Results from three national centres in China.2019Clinics and research in hepatology and gastroenterology
  3. Clinicopathological Characteristics, Surgical Treatments, and Survival Outcomes of Patients with Duodenal Gastrointestinal Stromal Tumor.2019Digestive surgery
  4. Laparoscopic resection of intestinal stromal tumors with transrectal extract specimen: A case report.2019Medicine
  5. Glomus Tumor of the Stomach-A Tumor That Needs to Be Differentiated From Gastrointestinal Stromal Tumor.2018Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  6. CT texture analysis can be a potential tool to differentiate gastrointestinal stromal tumors without KIT exon 11 mutation.2018European journal of radiologyRCT
  7. Clinicopathologic features, surgical treatments, and outcomes of small bowel tumors: A retrospective study in China.2017International journal of surgery (London, England)
  8. [Evaluation of a new closure technique of large defects after endoscopic full-thickness resection].2017Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  9. [Laparoscopic versus open wedge resection of gastric gastrointestinal stromal tumors: a non-randomized case-matched study].2016Zhonghua zhong liu za zhi [Chinese journal of oncology]

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 2 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 002025

23 hospitals in Beijing for neuroblastoma321 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncologyRadiation oncology

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 1 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

16 hospitals in Beijing for Ewing sarcoma134 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology
Papers it led1
  1. Sarcoma of the uterine cervix: experience of a single center.2024World journal of surgical oncology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Aplastic anaemia

再生障碍性贫血

Led 3 of the 412 English-language PubMed papers on aplastic anaemia with an author in mainland China, 2021–2025: 0.7%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 1120242025: 002025

6 hospitals in Beijing for aplastic anaemia63 hospitals in China for aplastic anaemia

No open trial on aplastic anaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesStem cell transplantChildren
Departments in papersMedical oncology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Beta thalassaemia

β 地中海贫血

Led 1 of the 312 English-language PubMed papers on beta thalassaemia with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

10 hospitals in Beijing for beta thalassaemia133 hospitals in China for beta thalassaemia

No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Fanconi anaemia

范可尼贫血

Led 1 of the 68 English-language PubMed papers on Fanconi anaemia with an author in mainland China, 2021–2025: 1.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

3 hospitals in Beijing for Fanconi anaemia40 hospitals in China for Fanconi anaemia

No open trial on Fanconi anaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 1 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

25 hospitals in Beijing for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

中国医学科学院肿瘤医院

National Cancer Center / Cancer Hospital, CAMS

北京

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look at the hospital's own pages linked above.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
National Cancer Center/Cancer Hospital; Shanxi Hospital Affiliated to Cancer Hospital; Chinese Academy of Medical Sciences Cancer Hospital; Cancer Hospital Chinese Academy of Medical Sciences; Chinese National Cancer Center/Cancer Hospital; Shanxi Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital; Cancer Institute and Cancer Hospital; National Cancer Center/ Cancer Hospital

Suggest a correctionDownload the data